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ABSTRACT
The present work describes the experimental investigation of the SH3 Lymphocyte protein 2
(SLy2) in the mammalian immune system. SLy2 is an adaptor protein which is physiologically
expressed in hematopoietic tissues as well as in heart, brain and placenta. SLy2 is located
on human chromosome 21 and was reported to be amongst a particular group of genes,
which were amplified in Down syndrome (DS) patients and which were proposed to con-
tribute to DS phenotypes. Aside from congenital heart defects and mental retardation, sus-
ceptibility to infections with Streptococcus pneumoniae is a common immunological problem
in DS patients. Notably, these infections represent the major cause of mortality in a Swedish
DS cohort.
In this work, the immunological role of SLy2 was examined with the help of a tg-SLy2 animal
model, that over-expresses SLy2 in B and T lymphocytes. The investigations unraveled a
novel intracellular mechanism by which abundance of B-1 lymphocytes and their capacity
to produce pneumococcal polysaccharide-specific antibodies were inhibited following SLy2
over-expression, suggesting that SLy2 amplification in human DS might contribute to a gen-
eral susceptibility to S. pneumoniae infections. This hypothesis was supported by additional
data from BALB/c and SLy2-/- mice. As previously reported, BALB/c mice were resistant to
S. pneumoniae infections, and SLy2-deficient mice generally showed improved adaptive im-
munity. Here we proved that BALB/c mice share important immunological phenotypes with
SLy2-/- mice, including a massive down-regulation of SLy2 in splenic B cells and increased
peritoneal B-1 cell abundance. In conclusion, the presented data strongly propose SLy2 as
an immuno-inhibitory adaptor protein, which might represent a potential future therapeutic
target for prevention of pneumococcal infections.
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ZUSAMMENFASSUNG
Die vorliegende Arbeit beschreibt die experimentellen Untersuchungen zur Funktion des
SH3 Lymphocyte protein 2 (SLy2) im Immunsystem von Maus und Mensch. SLy2 ist ein
Adapterprotein, das physiologisch in ha¨matopoietischen Geweben, sowie im Herzen, im
Gehirn und in der Plazenta exprimiert wird. SLy2 ist auf dem humanen Chromosom 21
lokalisiert und geho¨rt zu einer speziellen Gruppe von Genen, die bei Down Syndrom (DS)
Patienten amplifiziert sind. Es wird vermutet, dass diese Gene grundlegend zum Pha¨notyp
des Syndroms beitragen. Neben angeborenen Herzfehlern und mentaler Beeintra¨chtigung
sind Infektionen mit Streptococcus pneumoniae ein weit verbreitetes immunologisches Pro-
blem bei DS Patienten. Bemerkenswerterweise stellen diese Infektionen die Haupttodesur-
sache einer Schwedischen DS Kohorte dar.
In dieser Arbeit wurde die immunologische Rolle von SLy2 mit Hilfe eines tg-SLy2 Maus-
modells, welches SLy2 in B und T Lymphozyten u¨berexprimiert, untersucht. Die Forschungs-
arbeiten haben einen neuen intrazellula¨ren Mechanismus aufgedeckt, u¨ber den die Anzahl
von B-1 Zellen sowie ihre Fa¨higkeit Pneumokokken-Polysaccharid-spezifische Antiko¨rper zu
produzieren, durch eine U¨berexpression von SLy2 gehemmt wird. Die Ergebnisse lassen
vermuten, dass die Amplifikation von SLy2 in DS Patienten zu einer generellen Anfa¨lligkeit
fu¨r S. pneumoniae Infektionen fu¨hrt. Diese Hypothese wird durch zusa¨tzliche Daten von
BALB/c und SLy2-/- Ma¨usen unterstu¨tzt. Es ist bereits bekannt, dass BALB/c Ma¨use resistent
gegen S. pneumoniae Infektionen sind. Vor kurzem wurde auch fu¨r SLy2-defiziente Ma¨use
eine generell verbesserte adaptive Immunantwort gezeigt. Hier konnten wir zeigen, dass
BALB/c Ma¨use wichtige immunologische Pha¨notypen aufweisen, die sich mit denen von
SLy2-/- Ma¨usen decken. Dazu geho¨ren eine massiv verminderte Expression von SLy2 in B
Zellen aus der Milz und ein versta¨rktes Aufkommen von peritonealen B-1 Zellen. Zusammen-
fassend la¨sst sich sagen, dass die pra¨sentierten Daten SLy2 als ein immunsupprimierendes
Adapterprotein beschreiben, welches ein potenzielles zuku¨nftiges Zielprotein bei der Pra¨-
vention von Pneumokokken Infektionen darstellt.
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CHAPTER 1
INTRODUCTION
1.1 The family of SLy adaptor proteins
Adaptor proteins are involved in regulatory mechanisms, thus representing one adjustable
screw in cellular signaling pathways. Apart from enzymes, like phosphatases, proteases and
kinases, adaptor proteins have no catalytic activity. Hence, adaptors are not able to activate
or inactivate other proteins by phosphorylation, for example. However, via characteristic pro-
tein domains they exert protein-protein interactions, thereby stabilizing protein complexes
and regulating signaling cascades in an indirect manner in their function as so-called scaf-
fold proteins [71]. A multitude of adaptor proteins are known to particularly regulate B cell
signaling through their interaction with protein tyrosine kinases and phosphatases. Such
interactions are mediated by src-homology 2 (SH2) domains, that are able to recognize Ty-
rosine phosphorylation sites, or via SH3 domains, that preferably bind to Proline-rich peptide
sequences [55]. The importance of scaffold proteins in immune cells was reviewed in detail
by Shaw and Filbert, who reported about the critical functions of scaffolds during T cell acti-
vation, Ca2+-signaling, activation of the inflammasome, Toll-like receptor (TLR) signaling, as
well as formation of the immunological synapse [81].
An emerging family of adaptor proteins expressed in immune cells represents the SH3 Lym-
phocyte protein (SLy) family, including SLy1, SLy2 and the sterile-alpha-motif (SAM) and
SH3 domain containing protein 1 (SASH1). In 2001, SLy1 was discovered as the first mem-
ber of this family by Beer et al. [12]. In the same year, SLy2 (also termed HACS1, NASH1,
SAMSN1) was described [18, 91], and two years later, the third member, SASH1, was pub-
lished as a candidate tumor suppressor in breast cancer [103]. All members of the SLy
family express an SH3 and an SAM domain. Based on the strong sequence similarity in
their functional SH3 and SAM domains, SLy1, SLy2 and SASH1 were grouped into one
family of adaptor proteins [18, 104]. Although it is known that SLy1 is required for adaptive
immune responses in mice and is involved in marginal zone (MZ) B cell generation as well as
thymocyte development [11, 75, 79], the underlying molecular mechanisms still remain enig-
matic. Similarly, the specific roles for SASH1 and SLy2 in immune cells are under current
investigation.
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Introduction
1.1.1 SH3 Lymphocyte protein 2 - SLy2
The extensive study of a protein’s biochemical features, such as cellular localization, intracel-
lular shuttling, phosphorylation status and of course its interactome, remains indispensable
for understanding the mechanistic background of biological phenotypes. Murine SLy2 is lo-
cated on chromosome 16, encoding a protein composed of 364 amino acids [97]. SLy2 is
composed of a bipartite nuclear localization signal (NLS) at the N-terminus and a specific
phosphorylation site at Ser23 [14]. Furthermore, a nuclear export signal (NES) is predicted
within the SAM domain, ranging from amino acid number 270 to 275. The SH3 and SAM
domains, which are indicative of scaffolding functions, are located in the middle half and the
C-terminal part of the protein [18]. The domain structure of SLy2 is schematically illustrated
in Fig. 1.
Figure 1: Schematic illustration of the SLy2 protein. Colored boxes represent functional domains, NLS, SH3 and SAM
domain. Numbers stand for amino acids encoding the respective domains. Specific phosphorylation site Ser23 is highlighted
in red. C-terminally located SAM domain incorporates a potential NES (colored in violet).
Recently, 14-3-3 proteins were demonstrated to represent important cytosolic binding part-
ners of SLy2, which regulate its nucleo-cytoplasmic shuttling in an phosphorylation-depen-
dent manner [14]. In the nucleus, SLy2 was shown to interact with the Sin3A-associated
protein 30 (SAP30) and histone deacetylase 1 (HDAC1), forming a ternary complex that in-
creases HDAC1 enzymatic activity [14]. The deacetylating activity of HDAC1 represents a
major mechanism of epigenetic regulation of gene expression. Interestingly, the application
of specific inhibitors of HDAC activity are currently investigated in therapies of human mul-
tiple myeloma as well as acute myeloid leukemia [29, 60], two hematopoietic malignancies
where SLy2 was found to be strongly expressed [18, 65].
Further investigations on SLy2 binding partners revealed Cbl-b, RN-tre, SLP-65, SLP-76,
Gab-1, the intracellular domain of CD2, and cortactin to represent potential candidates [95].
Cortactin is an essential regulator of actin cytoskeleton rearrangements. Cell culture ex-
periments indicated an SH3 domain-dependent translocation of SLy2 to F-actin structures,
which are also targeted by cortactin in response to extracellular stimuli [95]. Interestingly,
actin cytoskeleton rearrangements promote cell spreading and the formation of immuno-
logical synapses [7].
Together, these studies demonstrate that the biologically relevant functions of SLy2 strongly
depend on its interactome, which is certainly cell type-specific and regulated by particular
intrinsic signaling cascades.
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SLy2 expression in humans
To get an idea of a protein’s place of activity and to identify cell types in which the protein
of interest may exert its biological functions, expression pattern analyses might be help-
ful. Human SLy2, which is conserved to its murine counterpart, was reported to be highly
expressed in myeloma, acute myeloid leukemia, lymphoma, normal bone marrow, lymph
nodes, spleen, and thymus, whereas lower levels were additionally found in the heart, brain,
placenta, and the lung [18]. Due to its preferred expression in lymphoid tissues, SLy2 is
proposed to have important immunological functions in vivo. In humans, SLy2 is located
on chromosome 21q11.2 and was found to be amongst a very particular group of amplified
genes in lymphoblastoid cells derived from Down syndrome (DS) patients [3]. Immunological
diseases are a major problem in DS patients, although congenital heart defects as well as
mental retardation represent the most public ones. This is noteworthy as to the fact that SLy2
is expressed in immune tissues as well as in heart and brain.
The role of SLy2 in the immune system
The expression of SLy2 in activated immune cells was recently examined by RT-PCR ana-
lyses of stimulated human peripheral blood B cells and murine splenic B cells [104]. It
was demonstrated, and confirmed by Western blotting, that SLy2 was up-regulated following
IL-4 stimulation, and this effect was synergistically enhanced by co-stimulation with CD40L
[104]. The authors concluded a role for SLy2 in B cell differentiation processes. Pheno-
type analyses of Hacs1-/- mice revealed an enhanced adaptive immunity in mice missing
SLy2, predicting it to be an immuno-inhibitory adaptor protein [97]. In particular, Hacs1-/-
mice showed increased humoral immune responses to Ficoll antigens, and increased B
cell proliferation following B cell receptor (BCR) stimulation, as well as increased humoral T
cell responses. Interestingly, cell population shifts were exclusively observed for peritoneal
B-1a cells, which were more abundant in Hacs1-/- mice, whereas other hematopoietic sub-
populations remained unchanged [97]. Similarly, a first phenotype analysis of tg-SLy2 (TG)
mice revealed that thymocyte development, peripheral T cell numbers, immature and mature
B cells, MZ and germinal center B cells as well as plasma cells were unaltered following
SLy2 over-expression [95]. However, purified splenic B cells from TG mice showed reduced
spreading on antigen-coated surfaces, emphasizing the role of SLy2 in actin cytoskeleton
rearrangements through the interaction with the lymphocytic cortactin homolog HS1 [95].
Together, these studies proposed SLy2 to act as an inhibitor of adaptive immunity and hypo-
thesized the association of SLy2 and the cortactin homolog HS1 to be one of the mecha-
nisms behind the immuno-suppressive function of SLy2 in vivo [95, 97].
Although these studies revealed important immunologic functions for SLy2, a detailed cell
type-specific mechanism, leading to the reported phenotypes of SLy2 mouse models, was
so far not identified. Especially with regard to the fact that SLy2 was over-expressed in DS
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patients and predicted to contribute to specific DS phenotypes [3], the present work aimed
to elucidate such a phenotype-genotype relation with the help of TG mice, over-expressing
SLy2 in lymphocytes. In the following sections, the immunological basics for the present
study will be introduced systematically.
1.2 Humoral immune responses
Humoral components of the immune system include all non-cellular substances, such as
complement factors, cytokines, and immunoglobulines (Igs). The entity of secreted Igs con-
stitute a specific effector of the humoral immune system. Dependent on the antigen stimulus,
Igs are produced and released from so-called antibody-secreting cells (ASCs) in order to
rapidly neutralize incoming pathogens.
1.2.1 Classification of antigens
Antigens are classified into distinct types, due to their ability to induce different arms of
immune responses. Two main classes of antigens can be distinguished, representing on
the one hand T cell-independent (TI) antigens, and on the other hand T cell-dependent (TD)
antigens. TI antigens are able to stimulate Ig production without the help of MHC class
II-restricted T cells [61]. In contrast, TD antigens associate with MHC molecules on antigen-
presenting cells (APCs) in order to activate T cells. As such, T cell activation is a prerequisite
for the generation of a proper immune response to these types of antigens.
T cell-independent antigens
According to the mechanism a B cell is activated, two categories of TI antigens are dis-
criminated. TI-1 antigens are B cell mitogens, that activate B cells independently of the
BCR. The prototypic TI-1 antigen represents lipopolysaccharide (LPS), which activates B
cells via TLR4.
Another route of B cell activation is induced by large polysaccharides (PS) derived from
encapsulated bacteria, such as Streptococcus pneumoniae (S. pneumoniae). These PS
are able to cross-link BCRs, which induces BCR signaling cascades. Such antigens are
classically categorized as TI-2 antigens. In experimental medicine, the synthetic PS Ficoll is
widely-used to study TI-2 antigen responses in model animals. TI-2 antigens mainly activate
MZ B cells and B-1 cells, whereas TI-1 antigens recruit all subsets of naive and memory B
cells [70]. Fig. 2 depicts the activation of B cells through BCR cross-linking by large PS,
leading to a differentiation to ASCs.
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Figure 2: B cell receptor cross-linking by polysaccharides. PS such as Ficoll or those derived from S. pneumoniae cause
BCR cross-linking. This is followed by a rapid activation of B cells and leads to the differentiation to ASCs, such as plasma
cells, which produce antibodies that target the PS antigen (adapted from [73]).
Taken together, the characteristic feature of TI antigens is their capacity to activate B cells
without being presented by MHC molecules to the respective T cells, thus enabling a very
rapid elimination of pathogens. However, TI responses basically don’t induce the generation
of memory B cells [61], and hence, omit the development of long-lasting immunity against
specific pathogens.
T cell-dependent antigens
Another group of antigens, which is composed of proteins or small peptides, contribute to
an activation of B cells with the help of T cells, and thus, are referred to as TD antigens.
These antigens are presented to activated T cells via MHC molecules. Activated cognate
B and T cells then meet at the interface between B and T cell areas in the spleen, and
elicit a very specific and productive immune response [70]. In the present study, chicken
gamma globuline (CGG) was selected to examine TD responses in mice. A great advantage
of TD immune responses is the generation of highly-effective immune responses and the
generation of memory B cells. Altogether, this type of immune reaction is comparatively
slow, however long-lasting and more sustainable than TI responses.
Antigens derived from Streptococcus pneumoniae
A closer view to the individual antigens derived from S. pneumoniae indicates that infections
always induce TI as well as TD responses. The encapsulated bacteria S. pneumoniae in-
clude a multitude of different antigens, which are recognized by immune cells and antago-
nized by humoral and cellular effectors. Protein antigens that elicit TD responses represent
pneumolysine, pneumococcal surface proteins, and pneumococcal surface antigen for ex-
ample [100]. Nevertheless, the most virulent antigens from S. pneumoniae are the capsular
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pneumococcal polysaccharides (pPS), which are serotype-dependent antigens that elicit TI
immune responses. Classically, pPS represent TI-2 antigens that activate B cells via BCR
cross-linking. Yet, recent studies provided evidence that cross-linking per se was not suf-
ficient to achieve an immune response at the highest level in mice [48]. It was shown that
secondary signals from IL-4 and CD40L were additionally required for effective pPS-specific
antibody production [47]. This finding clearly distinguishes pPS from the synthetic PS Ficoll,
where CD40L signals did not improve the immune response [46]. Furthermore, this points
out that Ficoll-based approaches are not inevitably sufficient to draw a general conclusion
on TI-2 antigen responses in animal models.
1.2.2 Immunoglobuline production upon antigen encounter
Antigen-specific antibodies represent indispensable humoral effectors, which are released
from ASCs, such as plasma cells. B lymphocytes are able to differentiate to plasma cells
upon antigen-induced activation. The subclasses of antibodies released from ASCs strongly
depend on the antigenic stimulus. In mice, IgG3 is the predominant subclass produced
upon TI-1 and TI-2 antigen contact, whereas TD antigens induce a IgG1 dominant response
[85]. Aside from the IgG isotypes, IgM antibodies are generally produced first following
antigen encounter. Moreover, pre-existing IgM, which is measurable in the serum without
any previous exposure to exogenous pathogens, plays an essential role in the innate immune
system, as it provides a rapid and broadly specific defense. The characteristic features of
this so-called natural IgM are outlined in the following paragraph.
Natural immunoglobuline M
Most of the existing basal serum antibodies are of the IgM isotype. This natural IgM is part
of the innate immune system and causes delay of pathogen replication in a first line defense
[10], owing to its features of being polyreactive to endogenous as well as exogenous anti-
gens. Polyreactivity is partly provided by its pentameric structure (Fig. 3), that enables a
stable antigen interaction, despite the low binding affinity [13]. Pre-existing soluble IgM ex-
erts protective effects for influenza virus infection as well as for infections with S. pneumoniae
[9, 16], and was shown to protect from cardiovascular events as well as autoimmune disease
[22, 56]. Notably, the majority of natural IgM is produced by B-1a cells [10, 13, 58], which
assigns these cells an important protective role for viral or bacterial infections.
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Figure 3: Pentameric structure of IgM. Pentamer formation is mediated by the joining (J) chain (adapted from [26]).
1.3 B-1 cells in the innate and adaptive immune system
B-1 cells constitute a particular population amongst B lymphocytes, which was first described
in 1983 as a spontaneously IgM-secreting splenic B cell population [38]. Apart from B-2
cells, which mainly include follicular B cells as well as MZ B cells, B-1 cells develop earlier
in ontogeny and constitute the predominant B cell population in the pleural and peritoneal
cavities [50, 37]. Moreover, these cells exert different effector functions as compared to
conventional B-2 cells, which represent the most important effectors of adaptive immune
responses. Although they are functionally diverse from B-2 cells, there is no distinct surface
marker that allows unambiguous identification of B-1 cells. Instead, they have to be identified
according to their function in addition to their surface marker expression pattern, which is
CD19hiCD23-CD43+IgMhiIgDvar, and CD5 expression further segregates B-1a (CD5int) and
B-1b cells (CD5-) [8]. Another surface molecule on B-1 cells represents the interleukin-5
receptor (IL-5R), which is also expressed by eosinophils and pre-plasmablasts [27].
1.3.1 Effector functions of B-1 cells
As indicated above, B-1 cells bear unique effector functions. Under steady state conditions
bone marrow and splenic B-1 cells produce about 80 % of all natural serum IgM antibodies
[10, 17]. The anti-inflammatory cytokine IL-10 is also B-1 cell-derived, which strongly argues
for a tissue-protective role of B-1 cells during immune responses [69].
Following antigen-induced activation, peritoneal B-1 cells migrate to the spleen and peri-
pheral lymph nodes, where they differentiate to specific IgM and IgA-producing plasma cells
[34, 66, 101]. Moreover, B-1 cell-derived antibodies were found in the respiratory tract in
response to influenza virus infection [16]. Notably, B-1a and B-1b cells have non-redundant
functions and represent an essential effector population during S. pneumoniae infections
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[35]. While B-1a cells were shown to protect from pneumococcal disease by the production
of natural IgM, B-1b cells importantly contribute to an adequate specific antibody-response
against capsular pPS.
1.3.2 B-1 cell development and self-replenishment
The question how B-1 cell abundance is regulated in vivo is still not fully clarified. Yet, two
important mechanisms ensure the maintenance of B-1 cell pools, which include on the one
hand de novo generation of B-1 cells from specific precursors, as shown in neonate as well
as in adult mice [25, 30, 36, 39, 62], and on the other hand B-1 cell self-replenishment,
representing a unique feature of this population [63, 86].
De novo generation of B-1 cells
B-2 cells are continuously re-generated from hematopoietic progenitors in the bone mar-
row, and recruited to secondary lymphoid organs. This is an accomplished and universally
accepted basic concept in immunology. For B-1 cells, however, this mechanism only in-
adequately explains their abundance in vivo. A specific bone marrow progenitor was first
described in 2006, and since, B-1 cells were thought to be mainly produced during fetal life
[62]. The presence of a specific B-1 cell progenitor was supported in 2011, when Ghosn
and colleagues found the latter in the adult mouse spleen [30]. Nevertheless, it is still a
matter of discussion whether B-1 cells are generated from a single specific progenitor, or
from a common B cell progenitor, that gives rise to either B-2 or B-1 cells, dependent on
the environmental conditions. These two hypotheses are referred to as the ’lineage hypo-
thesis’ and the ’induced differentiation hypothesis’, as extensively reviewed by Dorshkind and
Montecino-Rodriguez [25].
Apart from the maturation of newly-generated B-1 cells, self-replenishment still represents
a distinctive feature of mature peripheral B-1 cells [39]. This self-replenishment depends
on the expression of specific B-1 cell-intrinsic factors that drive or impede cell proliferation.
Amongst these, the cell-cycle regulator cyclinD2 represents a critical inducer of B-1 cell re-
newal [86], whereas siglecG was shown to be involved in the down-regulation of B-1 cell
survival through inhibition of BCR-induced Ca2+ influx into B-1 cells [41]. Moreover, the
cyclin-dependent kinase inhibitor p18 was reported to limit the size of the B-1a cell compart-
ment in a dose-dependent manner [74]. Hence, these B-1 cell-intrinsic proteins are critically
involved in B-1 cell homeostasis and might contribute to alterations in the size of B-1 cell
pools.
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IL-5Rα-dependent B-1 cell proliferation and differentiation
Another very important B-1 cell-specific regulator of cell proliferation and differentiation re-
presents the IL-5Rα, which is constitutively expressed on B-1 cells and eosinophils, and a
minority of 2-4 % of conventional splenic B cells [40, 90]. With the help of IL-5-/- mice and
IL-5Rα-/- mice, the importance of the IL-5R for regulating B-1 cell numbers in vivo was un-
equivocally demonstrated [53, 102]. Moreover, the administration of a monoclonal antibody
against IL-5, proved evidence for the involvement of IL-5 in homeostatic proliferation and sur-
vival of mature B-1 cells, and similarly IL-5Rα-/- mice showed impaired B-1 cell survival and
proliferation [63]. Interestingly, the predominant expression of the IL-5Rα on eosinophils and
B-1 cells was pointed out in IL-5-/- mice following oxazolone-induced contact sensitivity [44].
These mice exhibited no eosinophilic infiltration in the skin and produced no B-1 cell-derived
oxazolone-specific IgM. In addition to its non-redundant role in IL-5-induced B-1 cell proli-
feration, IL-5Rα expression was reported to accelerate the ASC differentiation program in B
cells [27]. Together, these studies prove substantial evidence, that the IL-5Rα is a master
regulator of B-1 cell proliferation and differentiation. In turn, B-1 cell abundance as well as
B-1 cell-specific antibody production strongly depend on IL-5Rα surface expression.
1.4 Regulation of IL-5Rα expression on B cells
A multitude of studies concern the IL-5Rα expression on murine eosinophils. Yet, the regu-
lation of IL-5Rα on B cells, and particularly on B-1 cells, is to date comparably less well
examined. Basically, the IL-5R consists of an α- and a β-chain. IL-4 was shown to induce the
expression of the functionally important α-chain, whereas β-chain expression was promoted
by cross-linking signals [98]. As to the fact that CD40L stimulation enhanced interleukin-4
receptor (IL-4R) expression and signaling in B cells [84], co-stimulation of IL-4 and CD40L
synergistically enhanced IL-5Rα expression in murine B cells [27]. Thus, these two B cell
mitogens efficiently contribute to the responsiveness of B lymphocytes to IL-5, whereas other
mitogens were shown to be ineffective [4, 43], concluding that IL-5-induced enhancement of
IgM production strongly depends on the B cell stimulus [43].
1.4.1 Transcriptional regulation of IL-5Rα expression
An important B cell-specific transcription factor represents OCT2, which was recently shown
to regulate IL-5Rα expression in B cells, leading to B cell differentiation to ASCs [27]. OCT2
was previously reported to be required for serum Ig levels in naive mice as well as in animals
immunized with TI antigens [19]. Furthermore, in mice reconstituted with OCT2-/- B cells,
the abundance of B-1 cells was significantly reduced, pointing to the significance of OCT2
for B-1 cell maintenance [42].
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OCT2 transactivating modifications and co-factors
The OCT2 protein is composed of an N-terminal Gln-rich region and a C-terminal Pro-, Ser-,
and Thr-rich region, which were both shown to be required for optimal OCT2 activation, par-
ticularly through Ser-phosphorylation [88]. In addition, an N-terminal negative regulatory do-
main (NRD) was found in the OCT2.3 isoform, and differential phosphorylation was demon-
strated to regulate OCT2 transcriptional activity in B lymphocytes [6]. Nevertheless, the
unique indispensable features of the transcription factor OCT2 were reported to depend on
its transactivation domain (TAD), C-terminally located to the protein’s DNA binding domain
(POU-domain) [20]. The domain organization of the transcription factor OCT2 is schemati-
cally represented in Fig. 4.
Figure 4: Schematic OCT2 domain organization. The N-terminal NRD was exclusively found in the OCT2.3 isoform,
whereas the two TADs and the POU domain were commonly present, except from the isoforms OCT2.4 and OCT2.5 (adapted
from [99]).
Aside from the transactivation of the transcription factor OCT2 by phosphorylation of func-
tional protein domains, the protein-protein interaction of OCT2 with the B cell-specific co-
factor OBF1 was reported to represent a molecular principle of OCT2 activation in B lympho-
cytes [99]. Together, cell-specific co-activation by OBF1 as well as the direct posttranslational
modification of OCT2 govern the transcriptional activity of the latter in B cells, and hence,
regulate the expression of OCT2 target genes, such as the IL-5Rα.
Fig. 5 provides an illustration of how OCT2 is involved in B cell differentiation to ASC in a TD
environment.
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Figure 5: Involvement of OCT2 in the regulation of ASC differentiation. A germinal center B cell is activated by IL-4
and CD40L, which promote IL-5Rα expression via the transcription factor OCT2. Following surface expression of the IL-5Rα
protein, IL-5 can induce a cell differentiation program through the expression of Blimp1 and IRF4, leading to the production
and secretion of antibodies (Igsec) (adapted from [27]).
1.5 Infections with Streptococcus pneumoniae in humans
Pneumonia represents the leading cause of death in children worldwide, according to the
recently revised fact sheet, published by the world health organization (WHO). Pneumonia
is caused by bacteria, viruses, or fungi, with S. pneumoniae being the most common cause
of bacterial pneumonia. Beside malnutrition and environmental factors, pre-existing infec-
tions and a generally compromised immune system represent critical risk factors. The Ger-
man Standing Vaccination Committee (STIKO) of the Robert Koch-Institute recommends
pneumococcal vaccination for children under the age of 2 years in order to reduce morbidity
of invasive pneumococcal disease and the resulting consequences [76]. Moreover, stan-
dard immunization with pneumococcal polysaccharide vaccines (PPV) is recommended for
elderly people from the age of 60 years on. Children and young adults with pre-existing
illnesses that affect the immune system, such as sickle cell anemia, HIV infections, respira-
tory diseases, metabolic diseases, as well as other acquired or innate immune defects are
furthermore strongly recommended to be vaccinated with either a pneumococcal conjugate
vaccine (PCV), or a PPV.
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1.5.1 Host genetic risk factors for pneumococcal disease
Susceptibility to infections with S. pneumoniae strongly depends on environmental factors
as well as on the health status of individuals. Yet, in the present era of genomics, more
and more effort was put on studies to elucidate the genetic basis of susceptibility and resis-
tance to infectious diseases. Although, some single nucleotide polymorphisms (SNP) were
described to be associated with pneumococcal disease, no polymorphism has been shown
to directly affect susceptibility in humans [15]. Alternative to human case-control studies,
which are influenced by many disturbing factors, animal-based approaches were more effi-
cient in uncovering host genetic factors that account for pneumococcal infections [49]. Com-
parison of different inbred mouse strains revealed that CBA/Ca mice were susceptible to
S. pneumoniae D39, whereas BALB/c recovered from infections, and thus, were considered
resistant [31, 49]. C57BL/6 mice were defined intermediate, showing a median survival time
of 74 hours [31]. Genome-wide comparison of SNPs within the genome of CBA/Ca and
BALB/c mice was recently performed [49], however, data on mouse strain-dependent gene
expression profiles for individual cell types are lacking.
Susceptibility to Streptococcus pneumoniae along with Down syndrome
As mentioned above, recurrent infections are a common problem in DS patients and signifi-
cantly contribute to increased morbidity and mortality. A recent study reported that infectious
diseases including pneumonia represent the primary cause of death in a Swedish DS cohort
[28]. Former investigations demonstrated that DS patients had significantly lower concen-
trations of serum IgM as compared to mentally retarded non-DS subjects [1]. Furthermore,
DS patients mounted a significantly lower immune response to a 14-valent pneumococcal
vaccine [67].
Aside from a general deficit of NK cells as well as T and B lymphocytes, T cell subpopu-
lations such as helper T cells, and cytotoxic T cells, were particularly reduced in DS pa-
tients, and this was most pronounced in DS children up to 2 years of age [23]. Decreased
overall lymphocyte counts may contribute to susceptibility to infectious diseases, however,
cell-intrinsic defects could additionally account for immunosuppression in DS patients. This
was suggested by a recent investigation, which showed that transitional and naive B cells
were reduced in absolute and relative numbers in DS patients, accompanied by a disturbed
humoral immune response [93]. However, to date there are no studies available that concern
B lymphocyte functionality in DS patients. Especially with regard to DS, that represents a
complex genetic disease, cell type-specific host genetic factors that contribute to a general
susceptibility to infections, need to be investigated.
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1.6 Aim of the present work
In due consideration of the significance of immunological problems in DS patients, and as
to the fact that gene expression of the immuno-inhibitory adaptor SLy2 was significantly en-
hanced in the latter, the present work focuses on the role of SLy2 in the mammalian immune
system. In addition, given that SLy2 was found to be expressed in acute myeloid leukemia
and multiple myeloma, the investigation of the function of SLy2 in human diseases was fur-
ther implicated. Therefore, the primary aim of this work was to examine the natural function
of SLy2 in immune cells. For this purpose TG and KO mice were used as model orga-
nisms. TG mice, that over-express SLy2 in T and B lymphocytes, and KO mice, that lack
SLy2 expression globally, were phenotypically analyzed by immunological and biochemical
approaches. Although, previous work already described an immuno-inhibitory role for SLy2,
detailed molecular mechanisms remained largely theoretical. Therefore, the present work
aimed to clarify an intracellular mechanism, by which SLy2 exerts its immuno-inhibitory func-
tion in vivo. The identification of such a potential genotype-phenotype relation, and its vali-
dation for human beings was the desired goal of this study, in order to value the significance
of SLy2 dysregulation in human malignancies, and to spark interest in the investigation of
the suitability of SLy2 as a future therapeutic target for immuno-modulatory strategies.
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MATERIALS
2.1 Laboratory equipment
Table 1: Laboratory equipment
Name Manufacturer Location
BD FACSCantoTMII BD Biosciences Heidelberg, Germany
Centrifuge 5810 R Eppendorf Hamburg, Germany
Centrifuge 5430 Eppendorf Hamburg, Germany
dry bath FB15103 Fisher Scientific Schwerte, Germany
Gel Doc Device Bio-Rad Laboratories Mu¨nchen, Germany
HERAcell incubator Thermo Scientific Schwerte, Germany
Heraeus Pico17 Thermo Scientific Schwerte, Germany
HERAsafe clean bench Thermo Scientific Schwerte, Germany
LightCycler R© 480 II Roche Mannheim, Germany
MACS Multi Stand Miltenyi Biotec Bergisch-Gladbach, Germany
Microscope PrimoVert Zeiss Oberkochen, Germany
MidiMACSTMSeparator Miltenyi Biotec Bergisch-Gladbach, Germany
MiniMACSTMSeparator Miltenyi Biotec Bergisch-Gladbach, Germany
NanoDrop Lite Peqlab Erlangen, Germany
peqSTAR 2X Gradient Thermocycler Peqlab Erlangen, Germany
QIAxcel Qiagen Hilden, Germany
Sunrise Tecan Crailsheim, Germany
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2.2 Disposable materials
Disposable materials that are not listed in Table 2, were ordered from Sarstedt, Greiner, BD Bio-
sciences, or Eppendorf.
Table 2: Disposable materials
Name Manufacturer Location
70 µm Cup Filcons BD Biosciences Heidelberg, Germany
96 well PCR-plate, white Greiner Frickenhausen, Germany
AMPLIseal
TM
Greiner Frickenhausen, Germany
Cell Strainer 70 µm BD Biosciences Heidelberg, Germany
Costar 96 well EIA/RIA plate Corning Amsterdam, Netherlands
MACS R© Separation Columns Miltenyi Biotec Bergisch-Gladbach, Germany
Micropipettes 10 µl Brand Wertheim, Germany
Microtainer R© SST
TM
Tubes BD Biosciences Heidelberg, Germany
PCR 12er-SoftStrips Biozym Biotech Trading Vienna, Austria
2.3 Buffers, solutions and media
All solutions were prepared in water (Millipore quality), and pH was adjusted using NaOH or HCl.
Antibody dilution buffer 10 mM HEPES
0.5 M NaCl
1 % BSA (w/v)
0.2 % Tween20 (v/v)
0.02 % NaN3 (w/v)
BBS (2x) 50 mM BES
280 mM NaCl
1.5 mM Na2HPO4x2 H2O
pH 6.95
Cell lysis buffer 50 mM Tris
150 mM NaCl
2 mM EDTA
5 % NP-40 (v/v)
Complete Mini (Protease inhibitor tablet)
PhosSTOP (Phosphatase inhibitor tablet)
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ELISA blocking buffer 500 ml PBS
5 % BSA (w/v)
ELISA coating buffer 5 mM Na2CO3
45 mM NaHCO3
pH 9.0
ELISA sample buffer 500 ml PBS
0.01 % BSA (w/v)
0.01 % CaCl2 (w/v)
0.01 % MgCl2 (w/v)
20 mM β-Mercaptoethanol
Erythrocyte lysis buffer 0.155 M NH4Cl
0.01 M KHCO3
0.1 mM EDTA
HEK293T culture medium 500 ml DMEM High Glucose
10 % FCS (v/v)
5 ml Penicillin/Streptomycin (100x)
2 mM L-Glutamine
LB-agar (500 ml) 10 g LB-medium
7.5 g Agar-Agar
autoclaved
LB-medium (500 ml) 10 g LB-medium
autoclaved
MACS buffer 500 ml PBS
0.5 % BSA (w/v)
2.5 mM EDTA
SDS-running buffer (10x) 30.3 g Tris
144.2 g Glycin
10 g SDS
1000 ml H2O
pH 8.3-8.8
SDS-sample buffer (5x) 10 % SDS (w/v)
30 mM Tris at pH 6.8
0.1 % Bromphenolblue (w/v)
45 % Glycerin (v/v)
25 % β-Mercaptoethanol (v/v)
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Separation gel buffer 0.75 M Tris
0.2 % SDS (w/v)
pH 8.8
Separation gel (12 %) 9 ml Separation gel buffer
1.8 ml H2O
7.2 ml Acrylamide
45 µl TEMED
135 µl 10 % APS
Stacking gel buffer 0.25 M Tris
0.2 % SDS (w/v)
pH 6.8
Stacking gel (6 %) 4.5 ml Stacking gel buffer
3 ml H2O
1.5 ml Acrylamide
8 µl TEMED
90 µl 10 % APS
Stimulation medium 500 ml RPMI
10 % FCS (v/v)
2 mM L-Glutamine
0.05 mM β-Mercaptoethanol (v/v)
TBS/T 50 mM Tris
150 mM NaCl
0.1 % Tween20 (v/v)
Tissue lysis buffer 500 mM KCl
100 mM Tris at pH 8.3
0.1 mg/ml Gelatine
1 % NP-40 (v/v)
1 % Tween20 (v/v)
500 µg/ml Proteinase K
Transfer buffer SDS-running buffer
20 % Methanol
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2.4 Chemicals and biological kits
Chemicals that are not listed in Table 3, were ordered in pro analysis quality from Merck, Roth, Serva,
or Sigma-Aldrich.
Table 3: General chemicals
Name Manufacturer Location
Amersham Hybond
TM
Membranes GE Healthcare Mu¨nchen, Germany
Annexin V BD Biosciences Mannheim, Germany
β-Mercaptoethanol 50mM Gibco R© Life technologies Darmstadt, Germany
Cell Wall Polysaccharides Statens Serum Institute Copenhagen, Denmark
Complete Mini Roche Mannheim, Germany
DMEM High Glucose GE Healthcare Mu¨nchen, Germany
FCS GE Healthcare Mu¨nchen, Germany
Imject Alum Themo Scientific Schwerte, Germany
L-Glutamine 200mM GE Healthcare Mu¨nchen, Germany
Mouse IL-5 Recombinant Protein eBioscience Frankfurt, Germany
NP-BSA Biosearch Technologies Novato, CA, USA
Nuclease-Free Water Qiagen Hilden, Germany
PBS Gibco R© Life technologies Darmstadt, Germany
Penicillin/Streptomycin GE Healthcare Mu¨nchen, Germany
PhosSTOP Roche Mannheim, Germany
Pneumococcal Polysaccharides Statens Serum Institute Copenhagen, Denmark
Pneumovax R©23 Sanofi Pasteur Leimen, Germany
Protein A Sepharose
TM
GE Healthcare Mu¨nchen, Germany
Recombinant Mouse IL-4 R&D Systems Wiesbaden, Germany
RPMI GE Healthcare Mu¨nchen, Germany
SA-HRP BD Biosciences Mannheim, Germany
SA-PerCP-CyTM5.5 BD Biosciences Mannheim, Germany
TNP-CGG Biosearch Technologies Novato, CA, USA
TNP-Ficoll Biosearch Technologies Novato, CA, USA
TNP-LPS Biosearch Technologies Novato, CA, USA
TRI R©Reagent Sigma-Aldrich Taufkirchen, Germany
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Table 4: Commercially available biological kits
Kit Description Manufacturer
Amersham ECL Detection Reagents Western blot detection Kit GE Healthcare
B-1a cell isolation Kit B-1a cell separation Miltenyi Biotec
Bio-Rad DC
TM
Protein Assay Protein estimation Bio-Rad
BIOTAQTMDNA polymerase Amplification of DNA in PCR Bioline
BDTMCompBeads Compensation particles set BD Biosciences
CD45R (B220) MicroBeads B cell separation Miltenyi Biotec
CD90.2 MicroBeads T cell separation Miltenyi Biotec
DuoSet R© Economy Pack Mouse IL4 and IL-5 ELISA R&D Systems
EasyBlot IgG Kit IB of precipitated proteins GeneTex
High-Capacity cDNA Reverse Tran-
scription Kit
cDNA synthesis Applied Biosystems
High Pure RNA Isolation Kit RNA isolation Roche
NucleoBond R© Xtra Maxi DNA preparation Macherey-Nagel
NucleoSpin R© RNA RNA isolation Macherey-Nagel
OneShot R©TOP10 Chemically Com-
petent E. coli
Transformation of DNA Invitrogen
SuperSignal West Femto Chemilu-
minescence Substrate
Western blot detection Kit Thermo Scientific
SYBR Green I Master qPCR reaction master mix Roche
TMB Substrate Kit ELISA detection Kit Thermo Scientific
Transcription Factor Buffer Set Intracellular FACS analysis BD Biosciences
Transcriptor High Fidelity cDNA
Synthesis Kit
cDNA synthesis Roche
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2.5 Oligonucleotides
All primers, that are listed in Table 5, were purchased from biomers.net, Ulm, Germany.
(Tm = melting temperature; Ta = annealing temperature)
Table 5: PCR primers
Target Length [nu] Sequence 5’-3’ Tm
[◦C]
Ta
[◦C]
ko neokana rev 23 gagaataggaacttcggaatagg 50.00 57.00
SLy2 fwd 22 ggatctcattgtgattccgtgg 56.00 57.00
SLy2 wt rev 22 gacttggagctgtcaatgtaac 48.00 57.00
tgSLy2 fwd 27 ctgaaggagactgtggttgagtggtgg 63.00 62.00
tgSLy2 rev 29 cttccatttgtcagttccctgtcatggac 64.00 62.00
cyclinD2 fwd 20 gctgtgcatttacaccgaca 52.00 60.00
cyclinD2 rev 20 acactaccagttcccactcca 51.00 60.00
IL-5 fwd 20 acattgaccgccaaaaagag 52.00 60.00
IL-5 rev 19 atccaggaaactgcctcgtc 51.00 60.00
IL-5Rα fwd 20 ggtcccggtatgcagttcta 52.00 60.00
IL-5Rα rev 21 ggaagaccctggttagatcctt 52.00 60.00
IPC fwd 20 caaatgttgcttgtctggtg 52.00 62.00
IPC rev 20 gtcagtcgagtgcacagttt 52.00 62.00
mβ-actin fwd 20 aaggccaaccgtgaaaagat 53.00 60.00
mβ-actin rev 21 gtggtacgaccagaggcatac 51.00 60.00
mSLy2 fwd 21 attgcagatccagaagacagg 51.00 60.00
mSLy2 rev 20 agaggcacggattccttttc 52.00 60.00
p18 fwd 21 aaatggatttgggagaactgc 52.00 60.00
p18 rev 22 aaattgggattagcacctctga 52.00 60.00
siglec-G fwd 21 tccgactaagagtggcctatg 51.00 60.00
siglec-G rev 22 gatgtgaaggattctcatgcaa 52.00 60.00
hβ-actin fwd 18 aaggccaaccgtgaaaagat 51.00 60.00
hβ-actin rev 20 gtggtacgaccagaggcatac 51.00 60.00
hSLy2 fwd 20 cctcttgtattcgccacaca 59.00 60.00
hSLy2 rev 20 aggaaagacacccaccttga 59.00 60.00
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2.6 Antibodies
2.6.1 Purified antibodies
Table 6: Purified antibodies
Antigen Manufacturer Species Clone
AKT Cell Signaling rabbit C67E7
CD3 BD Biosciences hamster 145-2C11
CD16/CD32 BioLegend rat 93
CD40 BD Biosciences hamster HM40-3
ERK1/2 Cell Signaling rabbit 137F5
HA-Tag Cell Signaling rabbit C29F4
IgM BD Biosciences rat R6-6O.2
IκBα Cell Signaling mouse L35A5
Myc-Tag Cell Signaling rabbit 71D10
OCT2 Novus Biologicals rabbit polyclonal
pAKT Cell Signaling rabbit D9E
pERK1/2 Cell Signaling rabbit D13.14.4E
pIκBα Cell Signaling mouse 5A5
pSer Abcam mouse PSR-45
2.6.2 Conjugated antibodies
Table 7: Conjugated antibodies
Antigen Manufacturer Species Application
CD4-Biotin BD Biosciences rat FC
CD8a-Biotin BD Biosciences rat FC
IgM-Biotin BD Biosciences rat ELISA
IgG1-Biotin BD Biosciences rat ELISA
IgG3-Biotin BD Biosciences rat ELISA
IgG-HRP Dianova mouse WB
IgG-HRP Cell Signaling rabbit WB
TCRγδ-Biotin BD Biosciences hamster FC
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2.6.3 Fluorescently labeled antibodies
Table 8: Fluorescently labeled anti-mouse antibodies
Surface antigen Fluorochrome Species Dilution Manufacturer
B220 APC rat 1:800 BD Biosciences
CD90.2 APC rat 1:2500 BD Biosciences
BP-1 (Ly-51) FITC rat 1:200 BD Biosciences
CD4 FITC rat 1:200 BD Biosciences
CD8a FITC rat 1:200 BD Biosciences
CD21/CD35 FITC rat 1:200 BD Biosciences
CD125 (IL-5Rα) FITC rat 1:200 BD Biosciences
F4/80 FITC rat 1:200 BioLegend
IgM FITC rat 1:200 BD Biosciences
Ly6G FITC rat 1:200 BD Biosciences
CD4 Pacific Blue rat 1:800 BD Biosciences
CD5 Pacific Blue rat 1:400 BD Biosciences
CD19 Pacific Blue rat 1:600 BD Biosciences
CD44 Pacific Blue rat 1:200 BD Biosciences
IgD Pacific Blue rat 1:100 BD Biosciences
CD11c PE rat 1:400 BD Biosciences
CD23 PE rat 1:400 BD Biosciences
CD25 PE rat 1:200 BD Biosciences
CD43 PE rat 1:400 BD Biosciences
CD138 PE rat 1:200 BD Biosciences
TCRγδ PE hamster 1:100 BD Biosciences
CD11b PE-Cy7 rat 1:400 BD Biosciences
IgM PE-Cy7 rat 1:200 BD Biosciences
CD5 PerCP-CyTM5.5 rat 1:100 eBioscience
CD8a PerCP-CyTM5.5 rat 1:500 eBioscience
CD11b PerCP-CyTM5.5 rat 1:100 eBioscience
Ly6G PerCP-CyTM5.5 rat 1:100 eBioscience
Ter119 PerCP-CyTM5.5 rat 1:100 eBioscience
35
Materials
Table 9: Fluorescently labeled anti-human antibodies
Surface antigen Fluorochrome Species Dilution Manufacturer
CD19 APC mouse 1:50 BioLegend
CD43 FITC mouse 1:100 BioLegend
CD27 Pacific Blue mouse 1:50 BioLegend
CD3 PE-Cy5 mouse 1:50 BioLegend
CD20 PerCP-CyTM5.5 mouse 1:50 BioLegend
2.7 Plasmid constructs
The pCG vector, expressing OCT2, was kindly provided by Prof. Winship Herr, University of Lausanne
[88]. SLy2-pEF/myc/cyto constructs, expressing myc-tagged SLy2, were previously generated by
Simone Brandt [14].
2.8 Animals
Gene-targeted SLy2-/- (KO) mice were recently generated from C57BL/6 mice by Max von Holleben
[94]. The transgenic over-expressing mice tg-SLy2 (TG) were generated by Miltenyi Biotec, as re-
cently described in [95]. C57BL/6 and BALB/c mice were ordered from Charles River Laboratories.
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CHAPTER 3
METHODS
3.1 Statistical analysis
Statistical evaluation was performed as indicated in the corresponding figure legends. Statis-
tical analyses were performed with GraphPad Prism software. Graphics were generated with
Corel PHOTO-PAINT, FlowJo, and GraphPad Prism softwares and figures were composed
with Corel DRAW.
3.2 Human material
Peripheral venous blood was obtained from ten patients with DS (mean age: 8.4 years)
and six non-DS-control subjects (mean age: 16.2 years). Serum IgM levels from DS pa-
tients were quantified during routine clinical visits. SLy2 mRNA expression was assessed
in a subgroup of six patients (mean age: 14.2 years) and six non-DS-controls (mean age:
16.2 years). This study was performed according to the recently revised Helsinki Protocol.
All patients signed an informed consent form and the institutional ethical committee of the
University of Tu¨bingen approved these analyses.
3.3 Animal experiments
3.3.1 Breeding of gene targeted mice
WT, KO and TG mice were kept under specific pathogen free (SPF) conditions in open cages.
Inbred offspring were backcrossed to their genetic background for at least six generations.
C57BL/6 and BALB/c mice were bred by CharlesRiver Laboratories and ordered on demand.
37
Methods
3.3.2 Selection criteria
Mice were selected and pooled in groups according to their genotype, which was controlled
by PCR. Experiments were performed with 9-14 weeks old mice. Age-matched WT animals
were used as controls. All animal work was performed according to the German animal care
regulations and approved by the local government (AZ 10.01.2012; PH5/11; PH6/12).
3.3.3 Preparation of lymphoid organs and sera
Mice were sacrificed by cervical dislocation after CO2 or isoflurane-induced anesthesia and
primary and secondary lymphoid organs were prepared. Peritoneal cells were obtained by
peritoneal lavage using a 18 G needle and a 5 ml syringe. Spleen and thymus were carefully
removed and homogenized using a 70 µm cell strainer. Spleen cells were centrifuged and
resuspended in erythrocyte lysis buffer in order to get rid of erythrocytes. Lysis was carried
out for 1 min at room temperature and stopped with 10 ml of ice cold PBS. Again cells were
centrifuged and resuspended in an appropriate volume of PBS. All centrifugation steps were
carried out at 4◦C and 500 g for 5 min. Finally, bone marrow cells were washed out of tibia
and femur using a 26 G needle and a 5 ml syringe and erythrocytes were depleted as de-
scribed.
For serum preparation, mice were anesthetized by isofluran and blood was taken retro-
orbitally with a 10 µl capillary. Blood was collected in Microtainer R© SSTTM tubes. Coagu-
lation was awaited for 30 min at room temperature, then tubes were centrifuged at 11000 g
for 2 min to spin down the clotted cells. Serum was carefully transferred into fresh tubes and
stored at -20◦C.
3.3.4 Immunization protocols
To study humoral immune responses to TI antigens, mice were immunized intraperitoneally
with 100 µg TNP-Ficoll in 200 µl PBS, 50 µg TNP-LPS in 200 µl PBS, and 1 µg Pneumo-
vax R©23 in 200 µl PBS, respectively. TNP-CGG antigens were used to examine TD res-
ponses. To this end, for each animal 5 µg TNP-CGG were diluted in 100 µl PBS and pre-
cipitated with 100 µl of Imject Alum, according to the manufacturer’s instructions. Sera were
collected retro-orbitally before and 4, 7, 14, and 21 days after immunization.
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3.4 Molecular Biology
3.4.1 Genotyping of mice
Earmarks were taken from three weeks old animals and tissue biopsies were subsequently
lysed with tissue lysis buffer. Lysis was carried out for at least 1 h at 55◦C. Thereafter,
lysates were cleared by centrifuging for 3 min at 2500 g. PCR was performed with specific
primers targeting the respective gene construct (Table 5). PCR products were subsequently
separated using the QIAxcel DNA analyzer. The product identifying TG mice was detected
at 578 bp, whereas WT samples showed no specific band. In addition, an internal positive
control (IPC) gene was amplified to ensure that the PCR worked properly. The IPC product
was detected in all samples at 220 bp.
Two PCR products from KO samples detected at 744 bp and 1015 bp identified a hetero-
zygous genotype. The single lower band at 744 bp identified KO animals and the single
upper band identified WT animals.
TG PCR run protocol
Initial denaturation: 5 min at 94◦C
30 cycles: 30 sec denaturation at 94◦C
40 sec primer annealing at 62◦C
60 sec primer extension at 72◦C
Final extension: 5 min at 72◦C
Table 10: TG PCR reaction mix
Component Volume Final concentration
H2O 17.8 µl -
10x NH4 Reaction Buffer 2.5 µl 1x
MgCl2 1.0 µl 2 mM
dNTP-Mix 0.5 µl 2 mM
tgSLy2 fwd primer 0.5 µl 0.2 µM
tgSLy2 rev primer 0.5 µl 0.2 µM
IPC fwd primer 0.5 µl 0.2 µM
IPC rev primer 0.5 µl 0.2 µM
BIOTAQTM DNA polymerase 0.2 µl 1 Unit
DNA sample 1.0 µl -
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KO PCR run protocol
Initial denaturation: 5 min at 94◦C
30 cycles: 30 sec denaturation at 94◦C
40 sec primer annealing at 57◦C
60 sec primer extension at 72◦C
Final extension: 5 min at 72◦C
Table 11: KO PCR reaction mix
Component Volume Final concentration
H2O 18.3 µl -
10x NH4 Reaction Buffer 2.5 µl 1x
MgCl2 1.0 µl 2 mM
dNTP-Mix 0.5 µl 2 mM
SLy2 fwd primer 0.5 µl 0.2 µM
SLy2 wt rev primer 0.5 µl 0.2 µM
ko neokana rev primer 0.5 µl 0.2 µM
BIOTAQTM DNA polymerase 0.2 µl 1 Unit
DNA sample 1.0 µl -
3.4.2 Quantitative real-time PCR
RNA isolation
Total cellular RNA was extracted using either an RNA purification Kit (Roche or Macherey-
Nagel) for single cell suspensions and cultured cells, or TRI R©Reagent and Chloroform/Iso-
propanol for whole tissue lysates, according to the manufacturer’s instructions. Optical den-
sity at 260nm was measured to assess RNA concentration. Lambert-Beer equation was
used for calculation.
cDNA synthesis
Reverse transcription of RNA was performed with the High-Capacity cDNA Reverse Trans-
cription Kit for transcription of 0.5-2.0 µg RNA or the Transcriptor High Fidelity cDNA Syn-
thesis Kit for the transcription of 50 ng - 0.5 µg RNA, according to the protocols provided.
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qPCR
SYBR Green assays were applied for qPCR reactions. Specific primers were used for each
target gene to be analyzed. For each reaction β-actin was used as a reference gene. An
internal positive control sample was run side-by-side for each gene, and fold values were
calculated for each sample. Primers were designed with the Universal ProbeLibrary Assay
Design Center from Roche and qPCR data was analyzed with the LightCycler R©480 software.
qPCR run protocol for SYBR Green assays
Initial denaturation: 5 min at 98◦C
45 cycles: 10 sec denaturation at 98◦C
10 sec primer annealing at 60◦C
10 sec primer extension at 72◦C
Final extension: 5 min at 72◦C
Table 12: qPCR reaction mix
Component Volume Final concentration
H2O 1.5 µl -
2x SYBRMaster 5.0 µl 1x
fwd primer 0.4 µl 0.4 µM
rev primer 0.4 µl 0.4 µM
cDNA 2.5 µl 6.5 - 50 ng/µl
3.4.3 Amplification and preparation of plasmid DNA
To gain appropriate amounts of plasmid DNA for transient transfection of HEK293T cells,
DNA had to be amplified with the help of competent bacteria.
Transformation of competent bacteria
OneShot R©TOP10 competent E. coli were thawed on ice. Then, 5 µl of provided plasmid
DNA was incubated with 25 µl of bacteria for 30 min on ice. Transformation was sub-
sequently induced by 30 sec heat-shock incubation at 42◦C, followed by 2 min incubation
on ice. Transformed bacteria were then pre-incubated at 37◦C in 200 µl SOC-medium in a
bacterial shaker before they were streaked on pre-warmed LB-agar plates, containing 100
µg/ml ampicillin.
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Plasmid preparation
Ampicillin-resistant single colonies were picked the other day and over-night cultures were
inoculated. To this end, one single colony was added to 400 ml of LB-medium, supplemented
with 100 µg/ml ampicillin to selectively culture transformed bacteria only. Bacteria were in-
cubated at 37◦C and 225 rpm over night in a bacterial shaker. Plasmid DNA was purified the
next day using the NucleoBond R©Xtra Maxi Kit according to the manufacturer’s instructions.
3.5 Protein Biochemistry
3.5.1 HEK293T cell culture
HEK293T cells were stored in liquid nitrogen in 1 ml RPMI supplemented with 20 % FCS,
and 10 % DMSO. Cells were quickly thawed on ice, washed with pre-warmed culture medium
and plated on cell culture dishes for cultivation. HEK293T adherent cells were routinely split
twice a week. To this end, medium was aspirated and cells were washed with fresh medium.
Approximately 1x106 cells were resuspended in 10 ml fresh medium and plated on 10 cm
dishes.
3.5.2 Transient transfection by calcium-phosphate
1x106 HEK293T cells were seeded in 10 ml on 10 cm dishes one day before transfection.
1 M CaCl2 was diluted 1:5 in H2O and 500 µl of dilution were prepared for each transfection.
Then, 7-10 µg plasmid DNA were added and samples were mixed. Subsequently, 500 µl of
2x BBS were added in a drop-wise manner. Samples were mixed and incubated for 10 min
at room temperature. Thereafter, medium of plated cells was refreshed and transfection mix
was added in a drop-wise manner. Plates were rocked and incubated for 48 h, before protein
lysates were prepared.
3.5.3 Lysis of primary and cultured cells
Cell lysis buffer was freshly supplemented with protease and phosphatase inhibitors. Primary
murine immune cells were washed with ice cold PBS and lysed in 10 µl cell lysis buffer per
1x106 cells. Cultured cells were washed in PBS and were lysed in 500 µl cell lysis buffer per
10 cm dish. Lysis was carried out for 30 min on ice, then lysates were cleared by centrifuging
at 13000 rpm and 4◦C for 15 min. Protein lysates were stored at -20◦C.
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3.5.4 Protein determination and SDS sample preparation
Protein content of lysates was determined with the Bio-Rad DC
TM
Protein Assay Kit according
to the standard protocol. Optical density was assessed with the Sunrise ELISA plate reader
at 700 nm. BSA samples with a concentration ranging from 0 - 2 mg/ml were measured
side-by-side for the calculation of a standard calibration curve. Protein content of lysates
was adjusted to 10 - 50 µg per 20 µl, and samples were boiled with 5 µl 5x SDS-sample
buffer for 10 min at 95◦C.
3.5.5 Western blotting
SDS gels composed of a 6 % stacking gel and a 12 % separation gel were poured either
freshly or in advance and stored at 4◦C. Electrophoresis was run for 1 h at 60 V and then for
an adequate period at 120 V in SDS-running buffer. Separated proteins were transferred on
a Hybond
TM
nitrocellulose membrane by wet blotting. Transfer was carried out for 60-90 min
and 100 mA per membrane at 4◦C in transfer buffer. Membranes were subsequently washed
in water to remove methanol residues, and then blocked for 1 h in either 5 % milkpowder
in TBS/T or 5 % BSA in TBS/T. Thereafter, blocking reagent was removed by washing in
TBS/T. Finally, membranes were incubated over night at 4◦C with primary antibodies, diluted
in antibody dilution buffer. Secondary HRP-linked antibodies were incubated the other day
for 1 h at room temperature after washing the membrane three times in TBS/T. HRP reaction
was induced with the ECL reagents or the SuperSignal West Femto Kit after washing again
three times in TBS/T, and chemiluminescence was visualized using the Gel Doc Device.
Pixel densities of bands were calculated using ImageJ software.
3.5.6 Immunoprecipitation
60 µl of Protein A Sepharose
TM
beads were washed three times with cell lysis buffer by inver-
ting the tube. Beads were centrifuged at 500 g for 2 min in a pre-cooled centrifuge. 500 µg
protein in 500 µl cell lysis buffer were used for precipitation. Protein lysates were incubated
for 1 h at 4◦C with specific antibodies for precipitation. Cell lysis buffer was used as negative
control sample. Then, lysates were combined with prepared beads and incubated over night
at 4◦C. The other day, lysates and beads were loaded onto chromatography columns and
supernatants were collected. Supernatants were stored at -20◦C for further analyses. Beads
were washed three times with cell lysis buffer and subsequently, precipitated proteins were
eluted with 50 µl of 95◦C pre-heated 2.5x SDS-sample buffer. Elution was repeated two
additional times. Centrifuging between washing and elution steps was carried out at 500 g
for 10 sec. Eluted proteins were finally analyzed by Western blotting. EasyBlot anti-Rabbit
or anti-Mouse IgG Kit was used as a secondary reagent in order to mask the 50 kDa signal
of the IgG heavy chain from the antibodies used for precipitation.
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3.6 Cell Biology
3.6.1 Enzyme-linked immunosorbent assay (ELISA)
Basal IgM ELISA
Basal IgM levels were assessed in sera, supernatants of peritoneal wash outs, and splenic
single cell suspensions. High binding 96-well plates were coated with 5 µg/ml purified anti-
mouse IgM in coating buffer over night. The other day, the plate was washed and blocked
for 1 hour with ELISA blocking buffer. Samples were diluted in ELISA sample buffer and
incubated for 2 hours on coated plates. HRP reaction was induced with TMB and read out
at 450 nm after detecting specifically bound mouse IgM with biotinylated anti-mouse IgM
antibodies and SA-HRP conjugates.
TNP-specific immunoglobuline ELISA
TNP-specific Ig levels were assessed in sera of immunized mice. High binding 96-well plates
were coated with 10 µg/ml purified NP-BSA in coating buffer over night. The other day, the
plate was washed and blocked for 1 hour with ELISA blocking buffer. Samples were diluted
in ELISA sample buffer and incubated for 2 hours on coated plates. HRP reaction was
induced with TMB and read out at 450 nm after detecting specifically bound mouse Ig with
biotinylated anti-mouse IgM, IgG3, and IgG1 antibodies and SA-HRP conjugates.
Polysaccharide-specific immunoglobuline ELISA
pPS-specific Ig levels were assessed in sera and peritoneal lavage supernatants of immu-
nized mice. To this end, high binding 96-well plates were coated with 1 µg/ml purified pPS
or 5 µg/ml Pneumovax R©23 vaccine in coating buffer over night at 37◦C. The other day, the
plate was washed and blocked for 1 hour at 37◦C with ELISA blocking buffer. Samples were
diluted in ELISA sample buffer containing 10 µg/ml cell wall polysaccharides and incubated
for 15 minutes at 37◦C to capture cell wall-specific antibodies. Then, samples were pipet-
ted onto coated plates and incubated for 2 hours at 37◦C. HRP reaction was induced with
TMB and read out at 450 nm after detecting specifically bound mouse Igs with biotinylated
anti-mouse IgM, IgG3 antibodies and SA-HRP conjugates.
Cytokine ELISA
IL-4 and IL-5 cytokine ELISAs were performed with commercially available kits according to
the manufacturer’s instructions. To this end, T cells were stimulated as described above, and
supernatants were analyzed.
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3.6.2 Magnetic cell sorting (MACS)
Isolated spleen cells were homogenized and depleted of erythrocytes. Cells were labeled
with CD90.2 MicroBeads to positively isolate T cells or B220 MicroBeads to positively select
B cells, and separated with LS Columns according to standard protocols provided by the
manufacturer. For specific isolation of peritoneal B-1a cells, peritoneal wash-outs of ten
mice per genotype were pooled and B-1a cells were isolated in multiple steps using the B-1a
cell Isolation Kit according to the protocol provided.
3.6.3 Ex vivo stimulation of primary lymphocytes
T cell receptor signaling
For Western blot analyses of TCR signaling, positively isolated splenic T cells from three
mice per genotype were pooled. T cells were resuspended in 7.5 ml of ice-cold stimulation
medium without FCS and three 15 ml tubes were prepared with 2.5 ml of cell suspension.
Then, cells were either kept unstimulated or stimulated with 2.5 µg/ml anti-CD3 at 37◦C for
5 min or for 5 h. Incubation was stopped with ice-cold PBS and cells were immediately lysed
in 750 µl cell lysis buffer per sample.
T cell cytokine production and release
24-well plates were coated over night with 5 µg/ml of purified anti-CD3 in 500 µl PBS per
well. Primary splenic T cells were isolated by MACS and resuspended in stimulation medium
with 10 % FCS at a concentration of 4x106 cells per ml. 2x106 cells were seeded per well
and incubated for 48 h at 37◦C. Thereafter, cells were harvested and RNA was isolated.
Supernatants were collected for cytokine ELISAs.
B cell signaling
For Western blot analyses of IL-4 and anti-CD40 signaling, positively isolated splenic B cells
from three mice per genotype were pooled. B cells were resuspended in 7.5 ml of ice-cold
stimulation medium without FCS and three 15 ml tubes were prepared with 2.5 ml of cell
suspension. Then cells were either kept unstimulated or stimulated with 10 ng/ml IL-4 in
combination with 2 µg/ml anti-CD40 at 37◦C for 5 minutes or for 5 hours. Incubation was
stopped with ice-cold PBS and cells were immediately lysed in 750 µl cell lysis buffer.
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IL-5-induced IgM production and release from B cells
2x106 purified splenic B cells were stimulated in 24-well plates in a volume of 500 µl. To
induce IgM production and release, cells were stimulated for 96 hours at 37◦C with medium
containing 10 ng/ml IL-4 plus 2 µg/ml anti-CD40 alone or in combination with 10 ng/ml IL-5.
Additionally, unstimulated cells were incubated to assess FCS-mediated IgM production.
After 96 hours, supernatants were collected and total IgM levels were measured by ELISA.
Stimulation of IL-5Rα expression on B-1 cells
To stimulate IL-5Rα expression on B-1 cells, peritoneal lavage cells or spleen cells were
incubated for 48 hours at 37◦C in stimulation medium containing 10 ng/ml IL-4 in combination
with 2 µg/ml anti-CD40. To this end, half of all peritoneal cells or 2x106 splenocytes were
stimulated in 500 µl in a 24-well plate. FACS analyses of IL-5Rα expression levels on B-1a
and B-1b cells were performed before and 48 hours after stimulation, and fold values were
calculated.
Stimulation of IgM production in B-1 cells
To measure intracellular IgM levels in B-1 cells, peritoneal lavage cells were incubated for
24 hours at 37◦C in stimulation medium alone or in medium supplemented with 10 ng/ml IL-4
in combination with 10 ng/ml IL-5 and 2 µg/ml anti-CD40. To this end, half of all peritoneal
cells were stimulated in 500 µl in a 24-well plate. FACS analyses of intracellular IgM levels
in peritoneal B-1a and B-1b cells were performed 24 hours after stimulation.
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3.6.4 Fluorescence activated cell sorting (FACS)
Fluorescence activated cell sorting was used as a standard method to analyze the abun-
dance of hematopoietic cell populations and the expression levels of cell-type specific intra-
cellular and surface proteins. All flow cytometry data were analyzed with FlowJo software.
Compensation controls
Flow cytometry using a BD FACSCantoTM II cytometer allows the simultaneous detection
of fluorescence in eight different colors, also referred to as channels. Each color absorbs
light within an individual range of wavelengths and accordingly emits like that. However,
there is always a spill-over of emission into other channels causing false positive signals.
After calibrating with single-colored samples, also referred to as compensation controls, the
BD FACSDiva software automatically calculates a compensation that counterbalances false
positive signals. For this purpose, BDTM CompBeads were applied according to the manu-
facturer’s instructions.
Surface staining protocol
Following organ preparation, cells were routinely kept on ice in PBS. Per 1x106 cells usu-
ally 50 µl of 2x-concentrated staining master mix were prepared. Previous to fluorescent
staining, 1x106 cells were resuspended in 50 µl of CD16/CD32 antibody dilution and in-
cubated for 10 minutes on ice in order to block unspecific binding to FcRs. Subsequently,
2x-concentrated master mix was added and cells were stained for 15 min in the dark. There-
after, cells were washed with 300 µl PBS and centrifuged at 4◦C and 500 g for 5 minutes.
Finally, 1x106 cells were resuspended in 150-200 µl PBS and flow cytometry was performed.
For analysis of apoptotic cells, stained cells were washed and resuspended in 50 µl Annexin
V (1:100). Then, cells were incubated for 15 minutes, before 200 µl PBS and 4 µl of pro-
pidium iodide were added in advance of cytometric analyses. Table 13 shows the individual
surface markers for lymphocyte subpopulations in the respective tissues.
Intracellular staining protocol
Cell surface antigens were stained as described above. Then, cells were fixed and permeabi-
lized with the Transcription Factor Buffer Set according to the protocol provided. Intracellular
staining of IgM was performed for 30 minutes at 4◦C. Cells were thoroughly washed with the
provided washing buffer, and subsequently analyzed by flow cytometry.
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Table 13: Gating of cell populations
Tissue Cell population Gating
Human peripheral blood Naive B cells CD19+CD3-CD20+CD43-CD27-
’B-1’ cells CD19+CD3-CD20+CD43+CD27+
Memory B cells CD19+CD3-CD20+CD43-CD27+
Pre-plasmablasts CD19+CD3-CD20-CD43+CD27+
Bone marrow Pre-B cells CD43lo/-IgM-B220+CD19+
Late pro-B cells CD43hiIgM-B220+CD19+
Common lymphoid progenitor CD43hiIgM-B220-CD19-
Pre-pro-B cells CD43hiIgM-B220+CD19-
B-1 progenitors Lin-CD43-IgM-B220loCD19hi
Peritoneal cavity B-1a cells CD19+CD43+IgMhiCD5int
B-1b cells CD19+CD43+IgMhiCD5-
Spleen B cells B220+
Mature B cells B220+IgMhiIgDlo
Immature B cells B220+IgMloIgDhi
Marginal zone B cells B220+CD21+CD23-
Germinal center B cells B220+CD23+PNA+
Plasma cells CD4-CD8-CD21-F4/80-B220+CD138+
Granulocytes CD90-CD19-CD11b+Ly6G+
Monocytes CD90-CD19-CD11b+Ly6G-
Dendritic cells CD90-CD19-CD11c+
Eosinophils CD90-CD19-CD11b+SiglecF+
B-1a cells CD19+CD43+IgMhiCD5int
B-1b cells CD19+CD43+IgMhiCD5-
Thymus DN1 cells CD90+TCRγδ-CD4-CD8-CD44+CD25-
DN2 cells CD90+TCRγδ-CD4-CD8-CD44+CD25+
DN3 cells CD90+TCRγδ-CD4-CD8-CD44-CD25-
DN4 cells CD90+TCRγδ-CD4-CD8-CD44-CD25+
Cytotoxic T cells CD90+TCRγδ-CD8+
T helper cells CD90+TCRγδ-CD4+
Double positive T cells CD90+TCRγδ-CD4+CD8+
Double negative T cells CD90+TCRγδ-CD4-CD8-
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RESULTS
4.1 Immune inhibition by SLy2 over-expression in vivo
Microarray analyses of human chromosome 21 transcripts revealed that SLy2 was amongst
a distinct group of genes, which are amplified in DS patients, and which are predicted to
contribute to characteristic phenotypes of the syndrome [3]. Beside mental retardation and
congenital heart defects, the immune system is severely affected in DS patients. Infec-
tions with S. pneumoniae are a major problem and represent the main cause of death in
a Swedish DS population [28]. However, concrete genotype-phenotype correlations remain
to be investigated. To get more insights into the relevance of SLy2 over-expression in the
mammalian immune system, the previously published tg-SLy2 mouse model, where SLy2
is over-expressed in B and T lymphocytes was analyzed in more detail [95]. The immune
system of these mice was characterized on systemic, cellular and molecular levels in order
to clarify the function of the adaptor protein SLy2, and its mechanism of action.
4.1.1 SLy2 expression in peripheral blood from Down syndrome patients and
tg-SLy2 mice
To validate the microarray data which were obtained from lymphoblastoid cells derived from
DS patients [3], peripheral blood samples from DS patients and age-matched controls were
analyzed by RT-PCR. In parallel, SLy2 expression was quantified in immune tissues of TG
mice to confirm significant over-expression and to validate the mouse model. RT-PCR as-
says revealed average 4.2-fold higher SLy2 mRNA levels in human DS patients, compared
to their age-matched controls (Fig. 6 A). The differences were statistically significant and
confirmed the microarray data. Analysis of SLy2 expression in primary immune tissues of
TG mice revealed an average 23-fold over-expression in the bone marrow, and 4158-fold
over-expression in the thymus compared to WT mice. In splenic B and T lymphocytes, over-
expression of SLy2 was by mean 104-fold and 649-fold, respectively (Fig. 6 B). Together,
these data were a prerequisite of the subsequent investigations, and were considered to be
confirmatory and supportive of previously published findings [3, 95].
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Figure 6: SLy2 mRNA expression in human peripheral blood and TG mice. (A) RT-PCR analysis of human peripheral
blood from DS patients and age-matched non-DS controls. Bars represent the means + SEM of n = 6 patients, presented as
fold of non-DS control. Asterisk indicates statistical significance (* p <0.05; Student’s t-test). (B) RT-PCR analysis of bone
marrow, thymus and splenic B and T cells from TG mice and WT animals. These data were analyzed together with Klaudia
Buljovcic. Bars represent the means + SEM of n = 4-6 mice per genotype, presented as fold of an internal positive control.
Asterisks indicate statistical significance (*** p <0.001; Student’s t-test).
4.1.2 Effect of SLy2 over-expression on the specific humoral immune system
The humoral immune response is composed of unspecific and specific mediators. Un-
specific mediators comprise complement factors, as well as cytokines and growth factors.
Immunoglobulines (Igs) derived from ASCs represent specific mediators of the humoral
immune system. Igs are present in the serum without any previous exposure to exoge-
nous pathogens. These antibodies are so-called natural antibodies, which are constitutively
produced from specific hematopoietic cell populations. Following invasion of exogenous
pathogens, the serum Ig titers can elevate significantly. These Igs represent very spe-
cific high affinity antibodies that were produced from activated ASCs and that were able
to neutralize incoming pathogens. The next presented results show the effects of SLy2
over-expression on specific humoral immune responses following stimulation with different
antigens.
Basal IgM levels in Down syndrome patients and tg-SLy2 mice
Analysis of basal IgM titers of inpatient DS subjects was performed during routine clinical
visits. Reference values for healthy individuals range from 40 - 170 mg/dl. Fig. 7 A shows
the serum IgM titers of individual DS patients, and the mean value of 34.3 mg/dl. This
evaluation reveals that basal serum IgM levels in a group of inpatient DS children was lower
by mean as compared to the reference values, which confirms published data [1]. In parallel,
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basal serum IgM titers as well as IgM levels in peritoneal wash-outs were assessed in TG
animals and WT controls. Serum IgM levels were significantly reduced by 50.5 % on average
in TG mice (Fig. 7 B, left panel). Also basal IgM concentrations in the peritoneal cavity were
slightly reduced in TG mice, however, differences were statistically not significant (Fig. 7 B,
right panel). These data suggest a role for SLy2 in the regulation of basal serum IgM titers,
that were maintained by innate B cells. Amongst these, B-1 cells, present in the peritoneal
cavity and the spleen, produce the majority of this so called natural IgM [10].
Figure 7: Basal IgM levels in DS patients and TG mice. (A) Serum IgM levels of inpatient DS children measured during
routine clinical visits. Solid black line represents the mean of n = 10 patients. (B) Serum and peritoneal basal IgM levels of
TG mice and WT controls, measured by ELISA. Peritoneal IgM levels were assessed in supernatants of peritoneal wash-outs
in a volume of 3 ml. Bars represent the means + SEM of n = 6-7 mice per genotype. Asterisk indicates statistical significance
(* p <0.05; Student’s t-test).
Immunoglobuline responses to T cell-dependent antigens
TD antibody production was investigated in WT and TG mice by immunization with CGG, a
common TD antigen. Antigen-specific IgM and IgG1 levels were continuously assessed by
ELISA before and 4, 7, 14, and 21 days following immunization. ELISA revealed that IgM pro-
duction was impaired in TG mice, however, differences were statistically not significant when
comparing all groups with pre-immune titers of WT mice (Fig. 8 A, left plot). Yet, Student’s
t-test analyses of separate values of day 4 and 7 post-immmunization revealed significant
reduction of 36 % by mean for serum IgM levels in TG mice at day 7 (Fig. 8 A, right panel).
Furthermore, IgG1 levels were assessed by ELISA and overall lower titers were found in TG
mice (Fig. 8 B, left plot). However, statistical significance was calculated exclusively for the
separate values of day 21 when tested with Student’s t-test. The mean difference in sera of
TG mice was 56 % compared to WT controls (Fig. 8 B, right panel). These data indicate,
that SLy2 slightly inhibits TD immune responses in vivo, however, the effects were varying
strongly amongst the individuals.
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Figure 8: T cell-dependent antibody responses in TG mice. (A) CGG-specific serum IgM levels of WT and TG mice. Left
plot depicts development of IgM titers followed over 21 days after immunization, shown as means ± SEM of n = 6-8 mice per
group from two independent experiments. Statistical analysis was performed by ANOVA and Bonferroni posttests. Right plot
shows the separate analysis of day 4 and day 7 values. Bars represent the means + SEM of n = 6-8 mice per genotype from
two independent experiments. Asterisk indicates statistical significance (* p <0.05; Student’s t-test). (B) CGG-specific serum
IgG1 levels of WT and TG mice. Left plot depicts development of IgG1 titers followed over 21 days, shown as means ± SEM
of n = 6-8 mice per genotype from two independent experiments. Statistical analysis was performed by ANOVA and Bonferroni
posttests. Right plot shows the separate analysis of day 21 values. Bars represent the means + SEM of n = 6-8 mice per
genotype from two independent experiments. Asterisk indicates statistical significance (* p <0.05; Student’s t-test).
Immunoglobuline responses to T cell-independent antigens
TI antibody responses were assessed in WT and TG mice by immunization with the clas-
sical TI-1 antigen LPS, or the synthetic TI-2 antigen Ficoll. LPS induces a direct B cell
activation via binding to TLR4, whereas the synthetic polysaccharide Ficoll activates B cells
via BCR cross-linking. IgM and IgG3 courses, which were followed over 21 days, are shown
in Fig. 9. LPS-specific IgM and IgG3 titers were not different between WT and TG ani-
mals (Fig. 9 A, B). Moreover, Ficoll-specific IgM and IgG3 production were comparable in
both groups (Fig. 9 C, D). These results demonstrate that classical TI immune responses
were not altered following SLy2 over-expression in vivo, suggesting no direct function for the
adaptor protein SLy2 in TLR4 and BCR-induced Ig production.
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Figure 9: T cell-independent antibody responses in TG mice. (A) LPS-specific serum IgM levels of WT and TG mice,
followed over 21 days after intraperitoneal immunization. Presented as means ± SEM of n = 6-8 mice per group from two
independent experiments. (B) LPS-specific serum IgG3 levels of WT and TG mice, followed over 21 days after immunization.
Presented as means± SEM of n = 6-8 mice per group from two independent experiments. (C) Ficoll-specific IgM and (D) IgG3
courses following immunization, presented as means ± SEM of n = 6-8 mice per genotype from two independent experiments.
Statistical analyses were performed by ANOVA and Bonferroni posttests.
Immunoglobuline responses to Pneumovax R© vaccine
Pneumovax R©23 (P23) is a 23-valent pPS vaccine, composed of pPS from 23 different
serotypes of S. pneumoniae. Classically, pPS belong to the group of TI-2 antigens, which ac-
tivate B cells via BCR cross-linking. However, pPS antigens are distinct to Ficoll antigens, as
pPS additionally require T cell-derived IL-4 and CD40L to induce a proper antibody response
[46]. Therefore, total Pneumovax R©-specific IgM responses were measured in the sera of im-
munized WT and TG mice. TG mice exhibited severely impaired antibody-responses com-
pared to WT animals, which were statistically significant from day 14 on (Fig. 10 A, left plot).
Separate t-test analysis of day 4 and day 7 values, also revealed a significant 28.6 % re-
duction of IgM levels at day 7 post-immunization (Fig. 10 A, right panel). In addition to
total P23-specific IgM production, courses of single pPS6B, pPS19F, and pPS4-specific
IgM levels were examined (Fig. 10 B, C). No differences between WT and TG animals
were observed for pPS6B-specific IgM levels, and pPS19F-specific levels were only slightly
lower in TG mice. However, pPS4-specific IgM responses were significantly reduced in TG
mice, as depicted in Fig. 10 C. According to P23-specific values, separate t-test analysis
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of day 7, also revealed a significant 42 % reduction of pPS4-specific IgM concentrations
(Fig. 10 C, right panel). Moderate differences were also observed in peritoneal wash-outs
at day 21 post-immunization, indicating that peritoneal IgM-producing cells were involved in
pPS-specific antibody responses (Fig. 10 D). IgG3 levels specific for pPS4 were comparable
between WT and TG animals (Fig. 10 E), which suggests a specific role for SLy2 in the
production and release of IgM following pPS antigen contact.
Figure 10: Pneumovax R©23-induced immune responses in TG mice. (A) Left plot: P23-specific serum IgM levels of WT
and TG mice, followed over 21 days after intraperitoneal immunization. Presented as means ± SEM of n = 6-8 mice per group
from two independent experiments. Asterisks indicate statistical significance (** p <0.01; *** p <0.001; ANOVA; Bonferroni
posttests). Right panel: Separate analysis of day 4 and day 7 values. Bars represent means + SEM of n = 6-8 mice per
genotype from two independent experiments. Asterisk indicates statistical significance (* p <0.05; Student’s t-test). (B)
Serum levels of pPS6B-specific (left plot) and pPS19F-specific (right plot) IgM of WT and TG mice, followed over 21 days
after intraperitoneal immunization. Presented as means ± SEM of n = 6-8 mice per group from two independent experiments.
(C) Left plot: pPS4-specific serum IgM levels of WT and TG mice, followed over 21 days after intraperitoneal immunization.
Presented as means ± SEM of n = 6-8 mice per group from two independent experiments. Asterisks indicate statistical
significance (* p <0.05; *** p <0.001; ANOVA; Bonferroni posttests). Right panel: Separate analysis of day 4 and day 7
values. Bars represent means + SEM of n = 6-8 mice per genotype from two independent experiments. Asterisks indicate
statistical significance (** p <0.01; Student’s t-test). (D) Peritoneal pPS4-specific IgM levels were assessed in supernatants
of peritoneal wash-outs in a volume of 3 ml at day 21 post-immunization. Bars represent the means + SEM of n = 7 mice per
genotype from two independent experiments. (E) pPS4-specific serum IgG3 levels of WT and TG mice, followed over 21 days
after intraperitoneal immunization. Presented as means ± SEM of n = 6-8 mice per group from two independent experiments.
All immunoglobulin titers were assessed by ELISA.
Altogether, investigations of specific humoral immune responses in WT and TG mice demon-
strated an inhibitory function for SLy2 in pPS-specific immune responses, whereas classical
TI antibody production via TLR4 and BCR activation remained unaffected. Moreover, TD
antibody production was impaired, which might be indicative for a potential involvement of
SLy2 in IL-4 and CD40L signaling, two important TD factors which essentially contribute to
proper pPS-specific responses [46].
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4.1.3 Influence of SLy2 over-expression on hematopoietic cell populations
In order to clarify the reasons for the observed deficits in IgM production in TG mice, the
abundance of cell populations of the hematopoietic system was analyzed by flow cytome-
try measurements. A variety of immune cell populations of primary and secondary immune
tissues from WT and TG mice were examined. Table 14 lists all populations that were quan-
tified. B and T cell precursors were examined in bone marrow and thymus, representing
the primary immune tissues. Mature B cell subpopulations as well as granulocytes, den-
dritic cells and monocytes were examined in the spleen, representing a secondary immune
organ. All populations that were analyzed were comparable between WT and TG animals,
concluding that SLy2 over-expression does not influence their abundance in vivo.
Table 14: Hematopoietic cell populations in WT and TG mice. FACS analysis of selected cell populations in primary and
secondary immune tissues of WT and TG mice. Values represent the means ± SD of n = 4-5 mice per genotype.
Tissue Cell population WT TG
Thymus DN1 cells 6.2 ± 3.0 4.7 ± 1.6
DN2 cells 1.5 ± 0.9 1.4 ± 1.0
DN3 cells 20.6 ± 9.4 20.4 ± 7.2
DN4 cells 71.7 ± 11.3 72.4 ± 8.6
Cytotoxic T cells 3.9 ± 1.2 3.6 ± 1.2
Helper T cells 9.5 ± 1.8 8.5 ± 1.9
Double positive T cells 83.7 ± 3.0 85.4 ± 3.2
Double negative T cells 2.9 ± 0.3 2.6 ± 0.4
Spleen B cells 54.3 ± 7.9 57.1 ± 6.2
Mature B cells 18.2 ± 4.8 20.5 ± 4.0
Immature B cells 65.5 ± 4.4 64.1 ± 4.5
Marginal zone B cells 9.6 ± 1.5 9.2 ± 2.6
Germinal center B cells 60.7 ± 14.4 64.5 ± 11.1
Plasma cells 5.9 ± 2.0 5.9 ± 1.6
Granulocytes 13.1 ± 2.9 14.6 ± 5.5
Monocytes 18.6 ± 4.6 20.2 ± 2.9
Dendritic cells 10.6 ± 1.8 12.7 ± 2.4
Eosinophils 0.8 ± 0.1 0.6 ± 0.1
Bone marrow Pre-B cells 40.3 ± 12.0 47.5 ± 5.7
Late pro-B cells 9.8 ± 1.7 6.5 ± 2.5
Common lymphoid progenitors 39.8 ± 12.4 36.6 ± 8.7
Pre-pro-B cells 43.2 ± 10.4 35.8 ± 6.0
BP1+ pre-B cells 2.8 ± 1.0 1.9 ± 0.9
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Peritoneal B-1 cells in tg-SLy2 mice
Having shown that there were no shifts in hematopoietic leukocytes and conventional B-2 cell
subpopulations in TG mice, we next addressed the abundance of B-1 cells. These cells were
of special interest, due to their characteristic feature of being the major source of natural IgM
as well as pneumococcal-specific IgM [10, 35]. Therefore, B-1 cell pools were analyzed by
flow cytometry in the peritoneal cavities and the spleens of WT and TG animals (Fig. 11 A).
Peritoneal and splenic B-1 cells were defined in the fraction of singlet lymphocytes as the
CD19+CD43+IgMhi-expressing population. CD5-expression further separates B-1 cells into
CD5int B-1a cells, and CD5- B-1b cells [51]. Analysis of flow cytometry data revealed by
mean a 26 % significantly smaller proportion of B-1a cells in the peritoneal cavities of TG
mice compared to WT controls (Fig. 11 B, left panel), whereas B-1b cells remained un-
changed (Fig. 11 B, right panel). In the spleen, B-1a cells were comparable in WT and
TG mice (Fig. 11 C, left panel). B-1b cells were slightly reduced in spleens of TG animals,
however, differences were statistically not significant (Fig. 11 C, right panel). These findings
indicate a function for SLy2 in down-regulating peritoneal B-1a cell abundance, which might
be one possible explanation for the significantly lower basal serum IgM levels, and the im-
paired IgM responses to pPS vaccination.
Figure 11: B-1 cell analysis in TG mice. (A) Flow cytometry analysis of peritoneal and splenic B-1a cells (CD5intIgMhi) and
B-1b cells (CD5-IgMhi) in the fraction of CD19+CD43+ lymphocytes of one representative individual per genotype, presented
as percentages of B-1 cells relative to singlet lymphocytes. (B) Mean percentages + SEM of peritoneal B-1a and B-1b cells
relative to singlet lymphocytes of n = 8 mice per genotype from three independent experiments. Asterisks display statistical
significance (* p <0.05; ** p <0.01; Student’s t-test). (C) Mean percentages + SEM of splenic B-1a and B-1b cells relative to
singlet lymphocytes of n = 8 mice per genotype from three independent experiments.
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B cell populations in DS patients
Interestingly, CD20+CD27+CD43+-expressing human B cells were claimed to represent the
analogs of murine B-1 cells, and these cells appeared to be involved in constitutive IgM
production as well as pPS-specific antibody responses in humans [32]. Although this cell
population shares some features with murine B-1 cells, the question whether these cells are
indeed the corresponding human B-1 cells still remains under debate [32, 92, 21]. A more
recent publication suggested human pre-plasmablasts to be the ”better” analogs of murine
B-1 cells [92]. Having shown that B-1 cells were reduced in SLy2 over-expressing TG mice,
we wondered about the abundance of the predicted B-1 cells in DS patients. To this end,
we analyzed human peripheral blood samples of one DS patient and one non-DS control
by flow cytometry. Selected B lymphocyte subpopulations including the two candidate B-1
cell populations were analyzed according to a recently published gating strategy [21]. Naive
and CD19+ B cells were clearly reduced in the DS patient, which confirms published data
[93] and validates our random samples (Fig. 12, left panel). Analysis of B-1 cells, memory
B cells, and pre-plasmablasts, however, was never examined in DS subjects before and our
preliminary result demonstrated a clear reduction, compared to the age-matched non-DS
subject (Fig. 12, right panel). This finding might be indicative for a potential involvement of
SLy2 in the characteristic immunological phenotypes of DS patients.
Figure 12: B cell analysis in human peripheral blood. Left panel: Flow cytometry analysis of naive B cells
(CD19+CD3-CD20+CD43-CD27-) and CD19+ cells in human peripheral blood of one individual per group. Right panel: Flow
cytometry analysis of B-1 cells (CD19+CD3-CD20+CD43+CD27+), memory B cells (CD19+CD3-CD20+CD43-CD27+), and
pre-plasmablasts (CD19+CD3-CD20-CD43+CD27+) in human peripheral blood of one individual per group.
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4.1.4 Maturation and apoptosis of B-1 cells in SLy2 over-expressing mice
In the TG mouse model we next addressed the reasons for the reduced peritoneal B-1a cell
population. Basically, an initial pool of B-1 cells is produced in the fetal liver [62]. In adult mice
the population maintains itself in the peritoneal cavity mainly by self-replenishment. Never-
theless, specific precursors in the bone marrow and spleen additionally give rise to mature
B-1 cells in adult mice [30]. These precursors were defined as IgM-CD43-B220loCD19hi-
expressing cells within the fraction of lineage negative lymphocytes [30]. To find out whether
SLy2 directly inhibits de novo maturation of B-1 cells from specific bone marrow progenitors,
the abundance of B-1 precursors in the bone marrow was assessed by flow cytometry. The
gating strategy for precursors is shown in Fig. 13 A. Analysis of flow cytometry data revealed
no significant differences when comparing WT and TG mice (Fig. 13 B), demonstrating that
SLy2 has no direct influence on de novo maturation of B-1 cells from specific bone marrow
progenitors.
Figure 13: B-1 cell bone marrow progenitors. (A) Gating strategy of bone marrow progenitors depicted for one representa-
tive individual. (B) Analysis of bone marrow B-1 cell progenitors relative to singlet lymphocytes, presented as means + SEM
of n = 5 mice per genotype from two independent experiments.
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To exclude that SLy2 promotes apoptosis of mature B-1 cells in the peritoneal cavity, thereby
contributing to reduced B-1a cell abundance in vivo, percentages of live, apoptotic, and
necrotic B-1a cells were additionally assessed in WT and TG mice by Annexin V and propidi-
um iodide staining. Analysis of flow cytometry data revealed no differences between the two
genotypes, when calculating the relative distribution of peritoneal B-1a cells into live cells,
cells in apoptosis stage I and II, and necrotic cells (Fig. 14 A). Discrimination of different
apoptosis stages by Annexin V and propidium iodide staining is demonstrated in Fig. 14 B.
The result of this flow cytometry-based experiment indicates that SLy2 is not directly involved
in B-1 cell apoptosis.
Figure 14: B-1 cell apoptosis in the peritoneal cavity. (A) Flow cytometry analysis of apoptotic and necrotic peritoneal B-1a
cells. Mean percentages of n = 4-5 mice per genotype + SEM from two independent experiments are shown. (B) Annexin V
and propidium iodide gating of peritoneal B-1a cells in apoptosis stage I or II, and necrotic cells of one representative individual.
Together, from the investigations on maturation and apoptosis of B-1a cells, we exclude a
direct role for SLy2 in down-regulating de novo generation of B-1 cells or increasing cell
degradation in vivo. Aside from these two important mechanisms regulating cell numbers
in vivo, B-1 cells are unique amongst the lymphocytes, as they are able to maintain their
population by self-replenishment with the help of multiple B-1 cell-extrinsic and B-1 cell-
intrinsic growth factors. In the following subsection these factors were therefore examined in
immune cells derived from WT and TG animals.
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4.1.5 The role of SLy2 in B-1 cell growth factor production
As mentioned before, B-1 cells are able to proliferate without preceding BCR stimulation.
This so called self-replenishment is mainly induced by T cell-derived cytokines, such as
IL-5 [63], which signals through the IL-5Rα-chain, expressed on B-1 cells as well as on
eosinophils. The expression of IL-5Rα in turn depends on IL-4 and CD40L stimulation of
B-1 cells [27]. Notably, IL-4 and CD40L were shown to be indispensable for proper immune
responses to pPS [47]. Therefore, production, release, and signaling of the B-1 cell-extrinsic
growth factors IL-5, IL-4, and CD40L were addressed in the following experiments. First,
T cell-receptor (TCR)-induced phosphorylation of downstream signaling proteins was inves-
tigated by Western blot analyses of isolated splenic T lymphocytes following stimulation with
anti-CD3. The TCR-induced signaling cascade leads to differentiation of T cells and pro-
duction of cytokines. Two important molecules were selected for phosphorylation analysis,
namely the protein kinase AKT and the downstream protein IκBα (Fig. 15). To this end,
WT and TG T cells were lysed without stimulation or following stimulation for 5 minutes
or 5 hours. Evaluation of Western blots revealed no differential phosphorylation of these
signaling proteins, indicating that TCR signaling was not essentially affected by SLy2 over-
expression.
Figure 15: anti-CD3-induced phosphorylation in T cells. Western blot analysis of unstimulated and anti-CD3 stimulated
splenic T cells. AKT and IκBα phosphorylation and protein levels in lysates of one representative experiment from two inde-
pendent assays. T cells from three animals per genotype were pooled for one assay.
Subsequent investigations addressed IL-4 release from T cells, and IL-4 and CD40L signa-
ling in B cells. To this end, IL-4 concentrations were assessed by ELISA in supernatants
of anti-CD3-stimulated purified splenic T cells from WT and TG mice. Evaluation of IL-4
cytokine ELISA yielded comparable concentrations in both supernatants (Fig. 16 A). Fur-
thermore, IL-4 and anti-CD40-induced phosphorylation of downstream kinases in purified
splenic B cells were analyzed by Western blotting. To this end, purified splenic B cells from
WT and TG animals were either lysed unstimulated or following stimulation with IL-4 and anti-
CD40 for 5 minutes or 5 hours. The two important downstream kinases AKT and ERK1/2
were selected for Western blot analyses (Fig. 16 B). Yet, evaluation of specific phospho-
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protein bands showed again no significant differences between WT and TG mice. These
data indicate, that SLy2 has no critical influence on IL-4 and CD40L signaling.
Figure 16: IL-4 release and signaling in T and B cells. (A) IL-4 ELISA of supernatants from unstimulated and anti-CD3-
stimulated splenic T cells of n = 6 mice per genotype + SEM from four independent experiments, presented as fold of un-
stimulated controls. (B) Western blot analysis of unstimulated and IL-4+anti-CD40-stimulated splenic B cells. AKT and ERK
phosphorylation and protein levels in lysates of one representative experiment from two independent assays. B cells from
three animals per genotype were pooled for one assay.
The last remaining and most important B-1 cell-extrinsic growth factor was IL-5. Hence,
the production of the latter as well as its release from T cells was extensively studied. To
this end, basal and TCR-induced IL-5 mRNA expression was assessed in purified splenic
T cells from WT and TG animals (Fig. 17 A). Although basal IL-5 mRNA levels (left panel)
were slightly reduced in TG mice, the differences were statistically not significant. Moreover,
TCR-induced IL-5 mRNA expression following stimulation with anti-CD3 for 48 hours was
not changed in TG mice, compared to WT animals (right panel). Accordingly, IL-5 releases
from purified splenic T cells were comparable, as measured in T cell culture supernatants
following 48 hours of TCR stimulation with anti-CD3 (Fig. 17 B).
Figure 17: IL-5 production and release of splenic T cells. (A) Left panel: RT-PCR of purified splenic T cells from n = 8
mice per genotype + SEM, presented as fold of an internal positive control. Right panel: RT-PCR of purified splenic T cells
following 48 hours of stimulation with anti-CD3. Values of n = 5 mice per genotype + SEM from four independent experiments
are shown as fold of unstimulated controls. (B) IL-5 ELISA of supernatants from unstimulated and anti-CD3-stimulated splenic
T cells of n = 8 mice per genotype + SEM from five independent experiments, presented as fold of unstimulated controls.
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These data further localize the site of action of the adaptor protein SLy2. Production and
release of IL-4 and IL-5 do not seem to be affected by SLy2 over-expression. Furthermore,
IL-4 and CD40L signaling remained unaltered. Hence, differential regulation of extrinsic B-1
cell growth factors was not the cause of the observed B-1 cell population shifts and ham-
pered B-1 cell functionality in TG mice.
4.1.6 B-1 cell-intrinsic alterations following SLy2 over-expression
Having shown that B-1 cell-extrinsic growth signals from T lymphocytes and IL-4 and CD40L
signaling in B cells were unaffected in SLy2 over-expressing TG mice, B-1 cell-intrinsic fac-
tors that control proliferation and differentiation were analyzed in more detail. The next ex-
periments aimed to clarify the mechanism behind reduced peritoneal B-1a cell numbers and
impaired immune responses to pPS vaccination.
Expression of B-1 cell-specific survival and proliferation genes
A variety of factors are known to control survival, proliferation, and differentiation specifically
in B-1 cells. The expression levels of three cell cycle regulators, namely cyclinD2, siglecG,
and p18 [41, 86, 74], were examined by RT-PCR in purified peritoneal B-1a cells from WT
and TG animals (Fig. 18 A). RNA was extracted from a pool of peritoneal B-1a cells of ten
mice per genotype. Analysis of data revealed no significant changes in mRNA expression
levels of these genes, demonstrating that SLy2 does not significantly influence B-1 cell cycle
through transcriptional regulation of cyclinD2, siglecG, and p18.
Yet, IL-5 still represents the major B-1 cell-extrinsic growth factor, as mentioned in the pre-
vious subsection. This T cell-derived cytokine specifically binds to the IL-5Rα on B-1 cell
surfaces to induce cell proliferation or differentiation [63, 27]. Therefore, IL-5Rα expression
in purified B-1a cells was additionally assessed. Evaluation of RT-PCR yielded a clear re-
duction of 90.6 % by mean in B-1a cells from TG mice compared to those of WT controls
(Fig. 18 B). This finding reveals a possible explanation for the distinct B-1 cell numbers and
B-1 cell functionality in TG mice.
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Figure 18: Expression analysis of B-1 cell growth factors. (A) RT-PCR analysis of cyclinD2, siglecG, and p18 in a pool
of purified peritoneal B-1a cells, washed out of ten mice per genotype. Bars represent the mean + SEM of three independent
RT-PCR assays, presented as fold of WT control. (B) RT-PCR analysis of IL-5Rα in a pool of purified peritoneal B-1a cells,
washed out of ten mice per genotype. Bars represent the mean + SEM of three independent RT-PCR assays, presented as
fold of WT control. Asterisk indicates statistical significance (* p <0.05; Student’s t-test).
Stimulation-induced expression of the IL-5Rα on B-1 cells
Previous results demonstrated a significant reduction of basal IL-5Rα mRNA transcription in
peritoneal B-1a cells. However, reduced transcription of genes is not stringently followed by
reduced protein levels on cell surfaces. Therefore, IL-5Rα (also referred to as CD125) protein
levels on B-1a cell surfaces were addressed in the next presented experiments. As described
before, IL-5Rα expression is promoted by stimulation with IL-4 and CD40L [27]. Hence, sin-
gle cell suspensions from peritoneal wash-outs and splenocytes were prepared from WT
and TG animals, and IL-5Rα expression was induced by ex vivo stimulation with IL-4 and
anti-CD40 for 48 hours. Thereafter, cells were analyzed by flow cytometry and IL-5Rα lev-
els were compared to those of unstimulated cells, measured two days before. Histograms of
FITC fluorescence intensity, which correlates with IL-5Rα (CD125) expression levels, show a
left-shift for peritoneal and splenic B-1a cells of the TG mouse as compared to a WT control
(Fig. 19 A). The mean fluorescence intensity (MFI) of CD125-FITC in the gate of B-1a cells
was assessed for stimulated and unstimulated samples, and induction of IL-5Rα expression
was calculated. Analysis of data revealed a significantly reduced up-regulation of 12.8 % by
mean on peritoneal B-1a cells, and on average 23.9 % less expression of IL-5Rα on splenic
B-1a cells (Fig. 19 B).
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Figure 19: B-1a cell surface expression of the IL-5Rα. (A) Flow cytometry analysis of IL-5Rα expression on stimulated
peritoneal and splenic B-1a cells. Solid black lines show histograms of CD125-FITC fluorescence intensity of one representa-
tive WT animal, solid grey lines represent those of one TG animal, and filled histograms depict isotype controls. (B) Analysis of
FITC MFI of stimulated cells normalized to unstimulated controls of n = 7-9 mice per genotype + SEM from three independent
experiments. Asterisk displays statistical significance (* p <0.05; Student’s t-test).
This finding proves that reduced transcription of IL-5Rα in B-1a cells from SLy2 over-expres-
sing TG mice results in compromised up-regulation of surface receptor levels following stimu-
lation with IL-4 and anti-CD40. The next experiments were performed to confirm the func-
tional consequences and to point out the relevance of this novel mechanism during Pneumo-
vax R©23 immunizations.
IL-5-induced IgM release from B cells
In brief, so far the most important findings were that basal and pPS-induced humoral IgM
responses were reduced in SLy2 over-expressing TG mice, and the expression of the re-
ceptor for the B-1 cell growth and differentiation factor IL-5 was impaired. Translationally,
this suggests that biological effects of T cell-derived IL-5 were impaired following SLy2 over-
expression. To examine the functional consequences of differential regulation of the IL-5Rα
on peritoneal and splenic B-1a cells, IL-5-induced IgM release from purified B cells was in-
vestigated. To this end, B220+ cells were purified from WT and TG spleens and stimulated
for 96 hours with IL-4 and anti-CD40 alone or in combination with IL-5. ELISA-based analysis
of cell culture supernatants apparently proved that IgM levels increased by stimulation when
compared to unstimulated samples, which were kept in stimulation medium supplemented
with FCS only (Fig. 20 A). Overall, TG mice produced less IgM in response to both stimu-
lations, however differences were statistically not significant. To assess the sole effect of
IL-5 stimulation, IL-5-induced IgM release was additionally calculated by normalizing values
from IL-5-stimulated samples to those of IL-4 and anti-CD40 stimulated samples (Fig. 20 B).
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These results provide evidence that IL-5-induced IgM production was significantly reduced
by average 21.7 % in samples from TG mice, confirming the functional defects that result
from reduced IL-5Rα expression levels on B-1a cells.
Figure 20: IgM release of purified splenic B cells. (A) IgM ELISA of supernatants from purified B cells, stimulated with
FCS, IL-4 and anti-CD40, or IL-5, IL-4 and anti-CD40. Bars represent the means + SEM of n = 5 mice per genotype + SEM
from three independent experiments. (B) Analysis of IL-5-induced IgM release of n = 5 mice per genotype. Bars represent the
means + SEM, normalized to IL-4 and anti-CD40 stimulated samples, from three independent experiments. Asterisk displays
statistical significance (* p <0.05; Student’s t-test).
Due to the limited abundance of B-1 cells, this experiment was performed with total splenic
B cells, including a large amount of B-2 cells, which are also capable to produce IgM. Al-
though IL-5Rα is a characteristic marker of B-1 cells, there was still lack of evidence that
the measured IgM was derived from B-1 cells only. In order to attest that IL-5-induced IgM
production was impaired in B-1 cells in particular, subsequent experiments were carried out.
IgM levels in B-1 cells following Pneumovax R© immunization
Although IL-4 and CD40L were reported to be essential for a proper immune response to
pPS [46], and these factors promote IL-5Rα expression on B-1 cells [27], a direct relationship
between IL-5 signaling and B-1 cell-derived pPS-induced IgM production was still missing.
In order to clarify this missing link in the presented novel relationship between SLy2 over-
expression and impaired pPS-specific humoral immune responses, intracellular IgM levels
were analyzed particularly in peritoneal B-1 cells following ex vivo stimulation with IL-5 and
following immunization of WT and TG mice with Pneumovax R©23. First, we wanted to attest
that reduced IL-5-induced IgM production, as demonstrated in Fig. 20, was based on de-
fective B-1 cells. To this end, peritoneal cells were stimulated for 24 hours with IL-4, IL-5,
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and anti-CD40. Flow cytometry analyses of intracellular IgM levels in B-1a and B-1b cells
revealed average 15.7 % lower IgM levels in B-1a and 24.2 % lower levels in stimulated B-1b
cells derived from TG mice as compared to WT controls (Fig. 21 A). This finding proved evi-
dence that B-1 cells in particular were the source of IL-5-induced IgM releases, which were
shown to be impaired in TG mice (Fig. 21), concluding that compromised IL-5Rα expression
results in lower humoral IgM responses when SLy2 is over-expressed.
Figure 21: IL-5 and P23-induced intracellular IgM in peritoneal B-1 cells. (A) Flow cytometry analysis of intracellular IgM
of peritoneal B-1a and B-1b cells, stimulated ex vivo with IL-4, IL-5, and anti-CD40 for 24 hours to induce IgM production.
Bars represent the means + SEM of n = 5 mice per genotype + SEM from three independent experiments, presented as fold
of unstimulated controls. Asterisks display statistical significance (** p <0.01; Student’s t-test). (B) Flow cytometry analysis
of intracellular IgM of peritoneal B-1a and B-1b cells at day 3 following intraperitoneal vaccination of WT and TG animals with
Pneumovax R©23. Bars represent the means + SEM of n = 6 mice per genotype + SEM from two independent experiments,
presented as IgM-FITC MFI.
Given that B-1 cells essentially contribute to pPS-specific immunoglobuline titers [35], we
attributed the defective Pneumovax R©23 responses observed in TG mice to the presented
B-1 cell-intrinsic functional alterations of IL-5Rα expression. Nevertheless, also other cell
types might be involved in mounting a pPS-specific immune response. To prove that defec-
tive B-1 cells in TG mice were the basis of this special phenotype, intracellular IgM levels
were measured by flow cytometry in peritoneal B-1 cells at day 3 post-immunization with
Pneumovax R©23 (Fig. 21 B). Analysis of data revealed slightly, however not significantly,
reduced IgM production in peritoneal B-1a and B-1b cells of TG mice. Since it is known
that in vivo activated peritoneal B-1 cells migrate to the spleen where they differentiate to
ASCs [34, 101], B-1 cell-specific IgM in isolated splenocytes from immunized animals was
additionally assessed. Analysis of MFI in splenic B-1a and B-1b cells clearly showed that
cells from TG mice contained significantly less intracellular IgM, than those of WT animals
(Fig. 22 A). IgM in B-1a cells was 11.6 % lower by mean in TG mice, and IgM in B-1b cells
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was 19.1 % lower by mean as compared to WT controls. Histograms of FITC MFI in splenic
B-1a and B-1b cells of one representative individual per genotype are presented as an over-
lay diagram (Fig. 22 B).
Figure 22: P23-induced intracellular IgM in splenic B-1 cells. (A) Flow cytometry analysis of intracellular IgM of splenic
B-1a and B-1b cells at day 3 following intraperitoneal vaccination of WT and TG animals with Pneumovax R©23. Bars represent
the means + SEM of n = 6 mice per genotype + SEM from two independent experiments, presented as IgM-FITC MFI.
Asterisks display statistical significance (* p <0.05; ** p <0.01; Student’s t-test). (B) Overlay of histograms representing IgM-
FITC fluorescence intensity of B-1a and B-1b cells of one individual animal per genotype. Solid black lines represent the WT
animal, solid grey lines represent one TG animal, and filled histograms depict isotype controls.
In summary, so far the presented data clearly show, that SLy2 over-expression results in re-
duced basal and Pneumovax R©23-induced IgM titers in vivo. Furthermore, B-1 cell-intrinsic
defects of IL-5Rα expression were shown to contribute to reduced IgM release in response
to IL-5 stimulation. Finally, we proved that these defective B-1 cells were the source of the
observed impaired IgM titers following vaccination of TG animals. These results reveal SLy2
as an important immuno-inhibitory adaptor protein for B-1 cell-mediated humoral immune
responses following BCR-independent activation, and thus, strongly propose the IL-5Rα to
be essential for proper responses to Pneumovax R©23 vaccine.
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4.2 Regulation of IL-5Rα expression by SLy2
Having shown that SLy2 regulates the transcription of the IL-5Rα in B-1 cells, the next pre-
sented experiments aimed to clarify the biochemical mechanisms behind. SLy2 is an adaptor
protein, which is localized in the cytoplasm as well as in the nucleus. Both compartments
may harbor potential interacting proteins. Candidate factors were those involved in control-
ling IL-5Rα transcription in B-1 cells. Literature searches identified the transcription factor
OCT2 as an interesting candidate, since it was shown to promote IL-5Rα expression ex-
clusively in B-1 cells [27]. This feature was important since we and others did not observe
any population shifts in IL-5Rα-positive eosinophils in mice globally missing SLy2 (data not
shown and [97]). Therefore, the transcription factor OCT2 was selected for a more detailed
biochemical characterization related to the presented immuno-regulatory process.
4.2.1 Co-precipitation of SLy2 with the transcription factor OCT2
In a first approach, constitutive binding of SLy2 to the transcription factor OCT2 was exam-
ined. To this end, primary splenic B cells from TG mice were purified and protein lysates
were prepared. As the transgenic SLy2 is HA-tagged, SLy2 was easily precipitated with
anti-HA antibodies. Following precipitation, lysates were analyzed by Western blotting and
checked for co-precipitation of OCT2. In parallel, buffer was used as a negative input control
(Fig. 23, lanes ”HA”). Similarly, OCT2 was precipitated from B cell lysates and checked for
SLy2-HA co-precipitation (Fig. 23, lanes ”Oct2”). However, Western blots showed no con-
stitutive co-precipitation in both cases, suggesting that OCT2 and SLy2 did not constitutively
co-precipitate in unstimulated splenic B cells.
Figure 23: Co-precipitation of SLy2 and OCT2. Immunoblot (IB) analysis shows protein content of HA-tagged SLy2 (left
panel) or OCT2 (right panel) following immunoprecipitation (IP) from stated inputs with either anti-HA or anti-OCT2 antibodies.
Negative control (-con): precipitation without antibodies. Input control (-): lysate without precipitation.
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4.2.2 Global Serine phosphorylation of OCT2 in presence of SLy2
Basically, the activity of transcription factors is strongly dependent on post-translational modi-
fications, such as phosphorylation or acetylation. For OCT2 in particular, differential phos-
phorylation at N-terminal and C-terminal Ser-phosphorylation sites was reported to control its
activity [88]. In general, the strength of Ser-phosphorylation positively correlates with OCT2
transcriptional activity [88]. Having shown that SLy2 does not constitutively bind to OCT2,
we suggested a more complex relationship that finally results in reduced transcriptional ac-
tivity of OCT2. Due to technical limitations in analyzing time- and stimulation-dependent
phosphorylation of 50 kDa proteins in primary B cells, a cell culture-based approach was
used for the following investigation. To this end, HEK293T cells were transiently transfected
with plasmid constructs to over-express OCT2, or were co-transfected with myc-tagged SLy2
(Fig. 24 A, left blots). OCT2 was precipitated of these protein lysates, and analyzed for the
amount of global Ser-phosphorylation by Western blotting (Fig. 24 A, right blots). Quantifica-
tion of Western blots was performed by normalizing phospho-Serine (pSer) bands to those
of precipitated OCT2. Mean values revealed a significant 17.7 % reduction of phosphory-
lated Serine following SLy2 co-precipitation, when compared to OCT2 transfected controls
(Fig. 24 B), indicating that the presence of SLy2 leads to an inhibition of global OCT2 Ser-
phosphorylation.
Figure 24: Phosphorylation of OCT2 in transfected HEK293T cells. (A) Left blots: Immunoblot (IB) analysis of protein
lysates transfected with either OCT2 alone, or in combination with myc-tagged SLy2. Right blots: IB analysis of immunoprecip-
itated (IP) OCT2 for global pSer. (B) Quantification of bands. Pixel density was measured for pSer and normalized to OCT2.
Bars represent the means + SEM of three independent experiments. Asterisk indicates statistical significance (* p <0.05;
Student’s t-test).
In summary, these initial findings from biochemical analyses revealed that SLy2 reduces
global phosphorylation of the transcription factor OCT2 in a cell culture-based approach.
As mentioned before, it is well-known that OCT2 transcriptional activity depends on its Ser-
phosphorylation status [88]. This strongly supports our hypothesis that SLy2 reduces OCT2
transcriptional activity, which is followed by an impaired IL-5Rα expression particularly in B-1
cells, leading to the presented immuno-inhibitory phenotype of TG mice.
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Fig. 25 A schematically illustrates the signal transduction in B-1 cells, leading to IL-5Rα
expression, which subsequently facilitates IL-5-dependent self-replenishment or differenti-
ation of B-1 cells into specific IgM-producing B-1 plasma cells. According to our findings
presented in this work, we propose this immuno-regulatory process to contribute to B-1 cell
self-replenishment as well as to the production of pPS-specific antibodies following vaccina-
tion with Pneumovax R©23. The involvement of the adaptor protein SLy2 is demonstrated in
Fig. 25 B, which illustrates the identical process for SLy2 over-expressing B-1 cells.
Figure 25: Schematic illustration of the role of SLy2 in B-1 cells. (A) IL4 and anti-CD40 signal via ERK and result in
OCT2-activating phosphorylation. This ends up in increased IL-5Rα expression in B-1 cells. The IL-5Rα subsequently gets
activated by T cell-derived IL-5 and induces B-1 cell self-replenishment under resting conditions, or B-1 cell differentiation into
IgM producing plasma cells under stimulated conditions, for example following Pneumovax R©23 immunization. (B) Inhibitory
effects of SLy2 are visualized by lighter lines and arrows, and less IL-5Rα and IgMs.
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4.3 Improved immune responses through decreased SLy2
expression
The previous sections demonstrated that SLy2 plays an important immuno-inhibitory role in
pPS-specific humoral immune responses through an IL-5Rα-dependent mechanism in B-1
cells. Due to the relevance of pneumococcal infections in DS patients, and the fact that
SLy2 is over-expressed in the latter, suitability of the adaptor protein as a target for immuno-
modulatory strategies comes into account. The so far presented data were based on SLy2
over-expessing model organisms, which showed inhibited pPS-specific immune responses,
as similarly observed in DS patients [67]. In turn, to improve immunity to S. pneumoniae in
human DS patients, the therapeutic aim would be to down-regulate the immuno-inhibitory
function of SLy2. This issue was concerned in the subsequently presented experiments,
which were based on the characterization of a SLy2-/- (KO) mouse model, recently gene-
rated by Max von Holleben [94]. Moreover, BALB/c mice were partially analyzed in paral-
lel, since a previous publication showed that BALB/c mice were resistant to infections with
S. pneumoniae [31]. The major goal of the next presented experiments was to validate the
findings from TG animals, and to bring out SLy2 as a novel potential host genetic factor con-
trolling susceptibility to pneumococcal infections.
4.3.1 Expression of SLy2 in BALB/c and SLy2-/- mice
As mentioned above, BALB/c mice were reported to be resistant to infections with S. pneu-
moniae [31]. Hence, the question came up whether SLy2 was involved in this phenotype.
With regard to this issue SLy2 mRNA expression levels were quantified by RT-PCR in pu-
rified splenic B cells of BALB/c mice and compared to those of cells from C57BL/6 mice.
C57BL/6 mice were used as controls, as these mice represent the genetic background of
SLy2-TG and KO mice. Analysis of RT-PCR data revealed a dramatically reduced expres-
sion level of SLy2 in BALB/c mice (Fig. 26 A). Concomitantly, purified splenic B and T cells
from KO mice were analyzed for SLy2 expression levels. Both cell types showed a significant
reduction of 99.9 % by mean (Fig. 26 B).
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Figure 26: SLy2 mRNA expression in BALB/c and KO mice. (A) RT-PCR analysis of SLy2 mRNA levels in purified splenic
B cells from C57BL/6 and BALB/c mice. Bars represent the mean + SEM of n = 5 mice per genotype, presented as fold of an
internal positive control. Asterisk indicates statistical significance (* p <0.05; Student’s t-test). (B) RT-PCR analysis of SLy2
mRNA levels in purified splenic B and T cells from WT and KO mice. Bars represent the mean + SEM of n = 5-6 mice per
genotype, presented as fold of an internal positive control. Asterisks indicate statistical significance (** p <0.01; *** p <0.001;
Student’s t-test).
4.3.2 Basal IgM levels in BALB/c and SLy2-/- mice
Investigations using TG mice clearly showed that SLy2 over-expression decreases natural
serum IgM levels. In contrast, analyses of serum IgM and splenic IgM levels in C57BL/6
and BALB/c mice revealed highly significantly increased titers for BALB/c mice, which were
2.1-fold higher by mean in the serum (Fig. 27 A, left panel), and 2.4-fold higher by mean
in the spleens (Fig. 27 A, right panel). In KO mice, a similar phenotype was observed,
showing average 1.5-fold higher IgM levels in the serum, and 1.9-fold higher IgM levels in
the spleens (Fig. 27 B, left panel and middle panel). Supernatants from peritoneal wash-outs
of WT and KO mice were additionally assessed, and revealed slightly increased IgM levels
in KO mice, although differences to WT mice were statistically not significant (Fig. 27 B,
right panel). Together, these results demonstrate that mice expressing less SLy2 in B cells,
yielded the opposite basal IgM phenotypes of SLy2 over-expressing TG mice, and support
the idea of a potential correlation between SLy2 expression and immunity to infections with
S. pneumoniae.
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Figure 27: Basal IgM levels in BALB/c and KO mice. (A) ELISA of total natural IgM in the serum and supernatants from
spleens of C57BL/6 and BALB/c mice. Bars represent the means + SEM from n = 6 sera per genotype, and n = 4 splenic su-
pernatants per genotype, calculated from OD450, presented as fold of an internal positive control. Asterisks indicate statistical
significance (*** p <0.001; Student’s t-test). (B) ELISA of total natural IgM concentrations in the serum and supernatants from
spleens and peritoneal wash-outs of WT and KO mice. Bars represent the means + SEM from n = 7-8 sera per genotype,
and n = 8 splenic supernatants per genotype, and n = 6 peritoneal supernatants per genotype. Asterisks indicate statistical
significance (* p <0.05; *** p <0.001; Student’s t-test).
4.3.3 Immunoglobuline responses to Pneumovax R© vaccine
The characteristic phenotype of SLy2 over-expressing TG mice was a significantly impaired
immune response to vaccination with Pneumovax R©23. Additionally, WT and KO mice were
immunized according to the identical protocol, in order to monitor specific IgM courses.
Pneumovax R©-specific IgM titers (P23) were measured in the sera of immunized WT and
KO mice. ELISAs revealed that KO mice exhibited improved antibody responses compared
to WT animals. Statistically significant differences were calculated at day 7 (Fig. 28, left plot).
In addition to total P23-specific IgM production, courses of the single polysaccharide-specific
IgMs were assessed for pPS4, pPS6B, and pPS19F (Fig. 28, from left to right). Obviously,
pPS4-specific IgM responses were significantly higher in KO mice at day 7, which was com-
parable to total P23-specific IgMs. Moreover, pPS6B-specific IgM was overall moderately
increased, whereas no significant differences were observed between WT and KO animals
for pPS19F-specific IgM levels. These findings clearly show reverse phenotypes as they
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were observed for TG animals, although effects were less pronounced. Nevertheless, these
data support the hypothesis that SLy2 essentially controls the humoral immune response
to pneumococcal polysaccharides, and foregrounds the basic necessity of investigating the
role of SLy2 over-expression and down-regulation during infections with S. pneumoniae.
Figure 28: Pneumovax R©23-induced immune responses in KO mice. From left to right: P23, pPS4, pPS6B,and pPS19F-
specific serum IgM levels of WT and KO mice, followed over 21 days after intraperitoneal immunization. Mean values ± SEM,
presented as fold of pre-immune titers of n = 7-8 mice per genotype from two independent experiments. Asterisks indicate
statistical significance (* p <0.05; ANOVA; Bonferroni posttests).
4.3.4 Peritoneal and splenic B-1 cell populations in BALB/c and SLy2-/- mice
As a final confirmatory experiment, B-1 cell abundances in the peritoneal cavities and the
spleens of BALB/c and KO mice were measured by flow cytometry. Interestingly, when com-
paring the sizes of B-1 cell pools in C57BL/6 mice with age-matched BALB/c mice, signifi-
cantly increased abundance of peritoneal B-1a as well as B-1b cells was found (Fig. 29, left
panels), confirming recently published data [44]. B-1a cell pools were on average 1.9-fold
increased, and B-1b cell pools were 1.8-fold increased by mean in BALB/c mice, giving an
explanation for the significantly higher basal IgM titers. However, B-1a and B-1b cell abun-
dances were significantly reduced by 29.4 % and 23.5 % in the spleens of BALB/c mice (Fig.
29, right panels), indicating that genetic variances, other than the marginal SLy2 expression,
also significantly control B-1 cell numbers in BALB/c mice.
Figure 29: B-1 cell abundance in C57BL/6 and BALB/c mice. Flow cytometry analysis of peritoneal and splenic B-1a and
B-1b cells of C57BL/6 and BALB/c mice. Bars represent the means ± SEM of n = 6 mice per genotype from two independent
experiments, presented as relative abundance within singlet lymphocytes. Asterisks indicate statistical significance (* p <0.05;
** p <0.01; *** p <0.001; Student’s t-test).
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Furthermore, analyses of B-1 cells in the peritoneal cavities and spleens of WT and KO ani-
mals revealed overall increased abundance of both, CD5intIgMhi B-1a cells, and CD5-IgMhi
B-1b cells (Fig. 30 A), which confirms and extends previously published data [97]. Evaluation
of flow cytometry measurements yielded a significant 1.2-fold increase of peritoneal B-1a
cells in KO mice (Fig. 30 B, left panel). Peritoneal B-1b cells were also increased, however,
these differences were statistically not significant. Moreover, splenic B-1a cells were 1.6-fold
increased and B-1b cells 1.5-fold (Fig. 30 B, right panel).
Figure 30: B-1 cell abundance in KO mice. (A) Flow cytometry analysis of peritoneal and splenic B-1a
(CD19+CD43+IgMhiCD5int) and B-1b cells (CD19+CD43+IgMhiCD5-) of WT and KO mice. FACS plots represent the abun-
dance of B-1 cells of one individual per genotype. (B) Analysis of flow cytometry data. Bars represent the means ± SEM of
n = 8-10 mice per genotype from three independent experiments, presented as relative abundance within singlet lymphocytes.
Asterisks indicate statistical significance (* p <0.05; ** p <0.01; Student’s t-test).
Together, investigations using BALB/c and KO mice, provided evidence, that SLy2 down-
regulation basically caused the opposite phenotypes of TG mice. Noting that BALB/c mice
were resistant to pneumococcal infections [31] and humoral immune responses to pneumo-
coccal vaccine were improved in KO mice, the presented study strongly proposes a critical
role for the adaptor protein SLy2 in immunity to S. pneumoniae.
Further investigations using WT, KO, and TG mice during pneumococcal infections will clari-
fy the relevance of the presented novel immuno-regulatory mechanism in vivo. Moreover,
these studies will be required to highlight the significance in human immunologic disorders,
as they are present in DS patients.
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DISCUSSION
5.1 Expression of SLy2 in human diseases
The genetic location of SLy2 on human chromosome 21q11.2 contributes to its significance
in DS, which is resulting from a complete or segmental trisomy 21. Interestingly, trisomy 21
is not stringently followed by a triplication of gene expression. In fact, the analysis of lym-
phoblastoid cell lines from DS patients revealed that the expression of most of the chromo-
some 21 transcripts was not altered. Only a fraction of 22 % of all transcripts (30 genes)
were over-expressed according to the gene-dosage effect and a minority of 7 % (9 genes)
were identified to be additionally amplified [3], as schematically illustrated below (Fig. 31).
Figure 31: Gene expression analysis of human lymphoblastoid cells. Class I genes were amplified about 1.5-fold, ac-
cording to the gene-dosage effect. Class II genes were more than 1.5-fold amplified. Class III genes were compensated, and
class IV genes were variably expressed and not grouped into one specific category (adapted from [3]).
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The nine class II genes, amongst which SLy2 was identified, were considered to determine
DS phenotypes, and thus, were of special interest to elucidate genotype-phenotype correla-
tions. The identified amplified genes might also represent interesting targets with regard to
all secondary malignancies along with DS. In the present work this microarray data was con-
firmed and validated by RT-PCR analysis of SLy2 expression in individual peripheral blood
samples.
5.1.1 Potential implications of SLy2 on Down syndrome phenotypes
Two relevant secondary malignancies along with DS represent leukemia and Alzheimer’s di-
sease [45, 52, 77]. In particular, the incidence of acute myeloid leukemia (AML) is increased
with DS [77], and also Alzheimer’s disease (AD) typically occurs in DS patients [52]. Notably,
SLy2 was found to be over-expressed in an AML-derived cell line, named KG-1a, as well
as in peripheral blood of AML patients [18]. Similarly, SLy2 was identified amongst a subset
of markers associated with AD. Therefore, it is tempting to speculate that SLy2 has indeed
a significant impact on AML development and AD, and this becomes apparent with human
trisomy 21. Moreover, due to SLy2 expression in heart and brain [18] it is conceivable that
the adaptor protein has a certain importance in other non-immunological DS phenotypes,
such as congenital heart defects and mental retardation, which results from a multitude
of defects in the brain (reviewed in [24]). Previous work reported that SLy2 affects actin
remodeling [95], which represents a basic mechanism underlying the formation of neuronal
synapses as well as muscle contraction [94]. Thus, investigations of SLy2 in heart and
brain represent eligible future fields of research, regarding the significance in human trisomy
21. An adequate murine model organism to study these genotype-phenotype correlations,
represents a previously published DS mouse model, in which SLy2 over-expression was
found in whole embryo RNAs [68]. Yet, the present study focused on the investigation of SLy2
in the immune system, given that DS is accompanied with a severely increased susceptibility
to infections.
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5.2 Murine model organisms for immunological investigations
The immune system is a complex integrative system composed of cellular as well as a mul-
titude of non-cellular components. To examine cell biology of immune cells, it is therefore
essential to keep them in their natural environment. Hence, for immunologists, the mouse
represents the experimental tool of choice to exemplarily study human biology. However,
there are significant limitations of such models, which need to be considered before extra-
polating data from mice to men [59]. Some important differences and general specifications
of the herein used mouse models are outlined in the subsequent paragraphs.
5.2.1 Tg-SLy2 and SLy2-/- mouse lines
In the present work, TG mice were used to investigate the significance of SLy2 over-expres-
sion in lymphocyte biology. The TG mouse is a valid model to study the role of SLy2 in
T and B cells, however, other cell types do not over-express SLy2 and were therefore not
considered for detailed functional analysis in this work. Hence, the TG animals represent a
simplified model to study the functional consequences of SLy2 over-expression in T and B
lymphocytes, in an otherwise wild-type-like environment.
On the contrary, KO animals lack SLy2 expression globally, and thus, do not represent a true
counterpart to TG mice. Immune cells other than lymphocytes might additionally contribute
to altered lymphocyte functionality in KO mice, complicating the analysis of cell type-specific
defects. However, the significance of the adaptor protein in the whole organism and in tissues
other than the hematopoietic system could be studied with the help of these animal models.
Altogether, these basic limitations of the utilized model organisms need to be minded when
interpreting the presented results.
5.3 Humoral immune responses in mice and men
With the help of TG animals, basal IgM levels as well as TI and TD immune responses were
assessed within this work. Significant differences were found in basal IgM levels and IgM
courses following Pneumovax R©23 vaccination. This corroborates with former publications
that reported reduced basal serum IgM levels in DS patients, and an impaired response to
pPS [1, 67]. Accordingly, generally reduced basal serum IgM titers were herein observed
in a random cohort of hospitalized DS children, confirming these earlier studies. However,
the limited number of test persons recruited in the present work did not allow to calculate
potential correlations with SLy2 expression levels. Moreover, three out of ten patients had
IgM levels within the reference range for healthy individuals, slightly weakening the value.
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5.3.1 Hospitalized patients versus SPF mice
A major limitation of the values obtained from human samples, represents their existing
health status. In fact, test persons were all hospitalized patients whose immune system
might be activated by in-house antigens or by any pre-existing malignancies. IgM represents
a sensitive parameter, which rapidly increases with small extrinsic or intrinsic immunological
activators. Therefore, the measured basal IgM levels might represent more or less biased
values. Large-scaled assessment of IgM levels and SLy2 mRNA expression in DS patients
and control subjects, under consideration of the pre-existing health status, would be of im-
portance to finally clarify a potential correlation between these two parameters. The data
obtained from TG mice are comparatively less influenced, due to the SPF housing condi-
tions, which ensure a low-grade pathogenic environment. Moreover, only healthy WT and
TG animals were used for experiments, thus preventing unwanted malignancy-induced im-
munological alterations. Together, the differences between WT and TG mice obtained from
murine studies are explained by different SLy2 expression only, whereas values from human
individuals might be the result of differences other than SLy2 expression.
5.4 Cell population shifts in mice and men
Changes in humoral immune responses are indicative of either functionally defective cells
or general alterations in the sizes of specific cell populations. Interestingly, in TG mice, ex-
clusively B-1 cells were changed in numbers whereas other hematopoietic subpopulations
remained unaltered. Due to the fact that B-1 cells mainly determine basal IgM titers and con-
tribute to pPS-specific immune responses [10, 35], these cells in particular were assigned
a crucial role in the present investigations. However, in DS patients it is well-known that a
variety of T lymphocyte subpopulations as well as certain B cell subpopulations were sig-
nificantly reduced in comparison to non-DS control subjects [23, 93]. Hence, the impaired
humoral immune responses can’t be simply attributed to one particular cell population in
these patients. It remains therefore speculative, whether altered B-1 cells alone contribute
to this immunological deficit.
5.4.1 Unequivocal identification of murine B-1 cells
The moderate differences in B-1 cell numbers of WT and TG mice do not adequately explain
the strongly reduced IgM response following vaccination. Therefore, functional examinations
of WT and TG B-1 cells were performed to elucidate potential B-1 cell-intrinsic defects. Yet,
such functional studies require the unequivocal identification of cell types. Although deve-
lopment, functionality, and the phenotype of murine B-1 cells are quite well characterized, it
remains challenging to examine B-1 cells in vivo, owing to their low abundance and the lack
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of a specific surface marker. For FACS analyses, B-1 cells have to be defined through a panel
of surface markers, which are all shared by other cell types [8]. Functionally, constitutive pro-
duction of natural IgM, and specific IgM production following TI antigen stimulation represent
the hallmark features of B-1 cells (reviewed in [8]). However, also MZ B cells participate
in antibody production to TI antigens [58]. Thus, B-1 cell identification by serum IgM levels
alone, likewise persists insufficient. Therefore, to unequivocally identify a true involvement
of B-1 cells in the phenotype of any mouse models, adoptive transfer experiments represent
the most significant approach. In the present work, no such adoptive transfer experiments
were performed. However, application of FACS analyses in combination with a set of func-
tional studies allowed to localize the source of the characteristic phenotype to the subset of
B-1 cells. Moreover, the IL-5Rα is a relatively secure marker of B-1 cells, which is otherwise
expressed on a minority of only 2-4 % of splenic conventional B-2 cells [40] and eosinophils,
that can be easily distinguished from B-1 cells. Nevertheless, these difficulties in B-1 cell
identification and distinction from other cell types might indeed influence the significance of
experiments, and could be responsible for attenuated read-outs or stronger variances. To
further highlight the specific involvement of B-1 cells in the present study, functional studies
on T and B cell signaling and cytokine releases were performed. The experiments clearly
indicated that the examined pathways remained unaffected and strengthened the hypothesis
that SLy2 regulates B-1 cell functionality. Nevertheless, it remains uncertain whether SLy2
is additionally involved in the function and behavior of cell types other than lymphocytes, for
example in IL-5Rα-expressing eosinophils. This will have to be terminally clarified in future
studies.
Tissue-distribution of B-1 cells in the mouse
Beside the characteristic functions in humoral immune responses, another feature of B-1
cells is their preferred residence in the pleural and peritoneal cavities. The relative distribu-
tion of B-1 cells in the steady state is given below (Fig. 32).
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Figure 32: Distribution of B-1 cells under steady state conditions. (Adapted from [8]).
According to this typical distribution, it appears plausible to examine B-1 cells primarily in the
peritoneal cavity. On the other hand, the low absolute cell number in the cavity again limits
the availability of B-1 cells. Furthermore, whenever B-1 cells are activated, they leave the
peritoneal cavity and migrate to the spleen and peripheral lymph nodes to become APCs
[34, 64, 66]. Therefore, identification of B-1 cells in vivo also requires a sensible selection of
immunologic tissues which are being analyzed. Hence, in this work B-1 cells were examined
in the peritoneal cavity as well as in the spleen, whenever possible. Overall, under consid-
eration of these technical limitations for an unequivocal identification of primary murine B-1
cells, the presented data strongly support a B-1 cell-specific function for SLy2, although a
definite proof by adoptive transfer experiments was not provided.
5.4.2 The ambiguity of human B-1 cells
As outlined above, murine B-1 cells are well-described in function, phenotype, and location.
However, in humans, the existence of B-1 cell analogs remains a matter of debate. In 2011,
CD20+CD27+CD43+CD70--expressing cells were found in human adult peripheral blood and
umbilical cord blood [32]. According to their capacity to produce natural IgM and their skewed
antibody repertoire, they were claimed to represent the counterpart of murine B-1 cells.
Moreover, these cells were then reported to produce pPS-specific antibodies following vacci-
nation with Pneumovax R©23 [92]. Nevertheless, another group proposed the identified cells
of rather being activated B cells on their way to plasma cell differentiation, instead of being an
eligible B-1 cell analog. This was further propagated by another study, which positioned the
predicted human B-1 cells somewhere between plasmablasts and memory B cells, showing
a pre-plasmablast-like phenotype rather than a B-1 cell phenotype [21]. Until now, this is
not fully clarified and the two groups still debate about the true human B-1 cell counterparts.
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Recently, a study with common variable immune deficiency (CVID) patients reported that the
proposed B-1 cells were reduced and this correlated with serum IgM levels [54], supporting
the B-1 cell-like phenotype for these cells. In the present work, the relative abundances
of predicted B-1 cells, memory B cells, and pre-plasmablasts were exemplarily analyzed in
peripheral blood samples of one DS patient and one control subject. Interestingly, all sub-
populations were reduced in the DS patient, which could be explained by the concomitant
reduction of naive and total CD19+ B cells [93]. Of course, the significance of this experiment
is very low, and much more patients will have to be recruited to confirm the reduced B cell
subsets, that phenotypically resemble murine B-1 cells. Moreover, still there are no studies
concerning the functionality of B-1 cells in DS patients, and owing to the ambiguity of human
B-1 cells it is arguable whether the presented murine studies on B-1 cell functionality can
simply be transferred across species.
5.5 Molecular connection between OCT2 and SLy2
In B cells, the transcription factor OCT2 was initially predicted to induce the expression of Ig
genes [19]. Later on, a variety of other target genes were identified in the lymphoid lineage,
demonstrating an important role for OCT2 during B cell differentiation [72]. The IL-5Rα re-
presents one target in B cells, mainly B-1 cells, which significantly governs IL-5-induced B
cell differentiation to ASCs [27]. In this work, SLy2 was demonstrated to be involved in the
transcriptional regulation of IL-5Rα expression in B-1 cells, suggesting that SLy2 is functio-
nally linked to the transcription factor OCT2. Moreover, Oct2 null mice and IL-5Rα-/- mice
had in part similar phenotypes as observed in TG mice, including reduced serum IgM levels
and reduced B-1 cell numbers [42, 102], which further suggests a molecular link between
these proteins. Nevertheless, the preliminary data from biochemical approaches into the
molecular connection did not reveal a direct constitutive co-precipitation in primary B cells.
At this point it is important to note that immunoprecipitation (IP) of OCT2 from primary B
cells was challenging due to its molecular weight of about 50 kDa, which is identical to the
weight of the Ig heavy chain. To reduce the unspecific signals from the Ig heavy chain of
native Igs from B cells or from the antibody used for precipitation, conformation-specific se-
condary reagents were used in Western blots. This successfully worked for the examination
of total proteins, however, when analyzing Ser-phosphorylation, the unspecific background
was still prevailing. To completely circumvent this problem, we therefore decided to use a
cell-line based approach for these purposes. The advantages were an easier handling, ow-
ing to the unlimited availability of cells, and an improved precipitation of OCT2 from lysates
of transfected cells, as compared to primary cells. Yet, the apparent disadvantage of this
approach represents the reduced validity for primary cells. Furthermore, the plasmid con-
structs expressing SLy2, as used in the present study, encoded the murine protein, whereas
HEK293T cells represent a human cell line. Thus, it remains uncertain whether the murine
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SLy2 was unrestrictedly functional in this human environment.
In future, appropriate biochemical approaches will have to be conducted to clarify the po-
tential molecular connection between OCT2 and SLy2. For example, mass spectrometric
analyses of OCT2 post-translational modifications in primary B cells from WT and TG mice
will be of value in order to elucidate whether SLy2 influences OCT2 transcriptional activity.
Interestingly, several candidate Ser-residues that account for transactivation or repression
of the transcription factor were identified within the OCT2 protein [2]. In conclusion, the
presented data might be indicatory for a potential interaction of SLy2 and OCT2, resulting
in reduced OCT2 Ser-phosphorylation, however, the consequent transcriptional activity was
not tested and remains to be investigated in future studies. Moreover, the presence and
activity of OCT2 co-activating factors, such as the B cell-specific co-activator OBF1 [33], will
have to be examined next. Altogether, a substantial biochemical analysis of the predicted
connection between SLy2 and OCT2 remains to be conducted in future experiments.
5.5.1 B cell-specific OCT2 target gene expression
Apart from IL-5Rα, other B cell-specific OCT2 target genes, such as the gene encoding
the scavenger receptor CD36, were formerly described [72]. In a first approach to address
OCT2 transcriptional activity in isolated B cells, CD36 mRNA expression was found to be
significantly reduced by 36.3 % on average in cells from TG mice, when compared to WT
cells (Fig. 33). With regard to the discussion of whether SLy2 and OCT2 are functionally
linked, this finding, further strengthens the hypothesis that SLy2 exerts its effects through
an interaction with the transcription factor OCT2 in murine B cells. Nevertheless, for the dif-
ferential regulation of CD36 mRNA expression, no functional effects on the immune system
were examined within this work. It is however important to mention that CD36 can recognize
amyloid fibrils, which may contribute to AD, as well as phosphocholine residues of pneumo-
coccal lipoteichoic acid, thereby reducing inflammation [80, 82].
Given that OCT2 has additional effects in other cell types as well, cell-specificity of the pro-
posed OCT2-SLy2 interaction represents indeed an interesting task. In T cells for example,
OCT2 contributes to the expression of IL-5 [78], which represents a major growth factor for
B-1 cells as well as for eosinophils. Yet, no population shifts in eosinophils were observed
in the TG mice, and resting, as well as anti-CD3-stimulated T cells did not show any dif-
ferent IL-5 mRNA expression and IL-5 release. Therefore, a critical role for SLy2 in T cells
is not supported by the present data and SLy2 is rather suggested to be important for B
cell-specific OCT2 target gene expression.
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Figure 33: CD36 mRNA expression in B cells. RT-PCR analysis of CD36 mRNA levels in purified splenic B cells from WT
and TG animals. Bars represent the means + SEM of n = 7 mice per genotype, presented as fold of an internal positive control.
Asterisk indicates statistical significance (* p <0.05; Student’s t-test).
5.5.2 OCT2 expression in the central nervous system
Regarding the relevance of SLy2 in DS patients, the question arises whether the predicted
interaction could be of value in cell types outside the hematopoietic system. As mentioned
in the introduction, SLy2 was found to be expressed in the brain [18]. Interestingly, also
OCT2 was found to be expressed in the central nervous system (CNS), especially in the
cerebellar cortex [57]. Moreover, OCT2 was reported to contribute to CNS development and
neuronal differentiation [87, 89]. Noting that mental disability in DS is mainly due to defective
neonatal neuronal development, it is tempting to speculate that SLy2 is partially involved
through the hypothetical interaction with OCT2, which in turn brings out an interesting future
field of research.
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5.6 A question of relevance and future perspectives
In summary, the present work describes a function for SLy2 in the inhibition of IL-5Rα ex-
pression on B-1 cells. As the IL-5Rα is important for B-1 cell proliferation as well as differenti-
ation to ASCs, SLy2 is suggested to regulate B-1 cell self-replenishment and IgM production
through this mechanism. This would explain the observed phenotypes in TG mice, which
were reduced B-1 cell numbers and reduced basal as well as specific IgM levels following
Pneumovax R©23 immunization. As these phenotypes were similar to those observed in DS
patients, and SLy2 was significantly amplified in the latter, a relevance for human disease
was assumed from the present work. However, as discussed before, it remains uncertain
whether murine data can uncritically be translated to humans. Moreover, the issue of B-1
cells and their identification in vivo, requests further studies with other mouse models to
ensure the presented novel molecular link between the IL-5Rα and pPS-specific IgM pro-
duction. In particular, the importance of IL-5Rα expression for Pneumovax R©23-induced IgM
responses could be additionally examined in IL-5Rα-/- mice. The here described findings
would be of great value, if SLy2 was investigated as an adaptor protein that down-regulates
the immune response to infections with S. pneumoniae. Then, SLy2 would represent an
interesting target for immuno-modulatory therapies, especially for immuno-compromised in-
dividuals, like DS patients.
Furthermore, the investigation of SLy2 in cells outside of the immune system would be of
great value for DS patients, when considering the promising constellation of SLy2 and OCT2
expression in the brain. However, this in turn requires a fundamental revealing of the definite
molecular link between SLy2 and OCT2.
The data presented in the last part of this work, using BALB/c and KO mice, were conducted
in preparation of the future investigation of SLy2 during infections with S. pneumoniae, in
order to clarify the relevance of SLy2 for pneumococcal diseases. KO mice showed im-
proved responses to Pneumovax R©23 immunization, further supporting an immuno-inhibitory
role for SLy2. A previous publication already suggested SLy2 to be a useful target for im-
mune suppression therapy, according to their analyses of Hacs-/- mice [97]. The authors
showed that mice lacking functional SLy2 had an increased peritoneal B-1a cell pool, in-
creased B cell proliferation following BCR stimulation, as well as improved Ficoll-specific IgM
and IgG3 responses, when compared to WT controls. Moreover, Th1 and Th2 responses
were reported to be significantly stronger in Hacs-/- mice [97]. Altogether, a multitude of
immunological phenotypes were examined in this study showing overall immuno-inhibitory
effects for SLy2, however, neither a concrete immunological context, nor fundamental bio-
chemical approaches were provided by this article. Therefore, the proper investigation of
SLy2 in coherence of infections remains to be addressed in future studies.
85
Discussion
5.6.1 Susceptibility to S. pneumoniae infections
A recent study compared the survival of different mouse strains following S. pneumoniae
infections [31]. As a result, BALB/c mice were identified to be resistant to these bacterial
infections. Interestingly, SLy2 mRNA expression in purified splenic B cells was much lower
in BALB/c, when compared to C57BL/6 mice, as demonstrated in this work. The hypothesis,
that SLy2 amplification contributes to susceptibility to S. pneumoniae was supported by the
data obtained from KO mice, which showed a largely reverse phenotype to TG mice, and
which shared some phenotypes with BALB/c mice, including an increased number of B-1
cells and increased IgM levels. In turn, for KO mice an increased survival for S. pneumo-
niae infections would be expected when extrapolating these findings. However, phenotypes
were not consistently comparable between BALB/c and KO mice. For example, B-1 cell
abundance was increased in the peritoneal cavity of BALB/c mice, which confirms recent
data [44], however a significantly reduced abundance was found in the spleen, when com-
pared to C57BL/6 mice. At this point it is important to mention that SLy2 was observed to
be significantly reduced in splenic B cells from BALB/c mice, however, expression levels in
thymocytes were significantly increased (data not shown), and further cell types were not
analyzed in these mice at all. In KO mice on the contrary, a lack of SLy2 expression was
demonstrated in splenic T cells and otherwise expected for all cell types [94]. Hence, to bring
out SLy2 as a host genetic factor for controlling susceptibility to pneumococcal infections, the
establishment of an infection model represents the subsequent approach with KO and TG
mice. The results will shed light on whether SLy2 plays a relevant role in human DS patients,
who suffer from recurrent pneumococcal infections.
5.6.2 Targeting SLy2 - A key to novel therapeutic strategies?
Speculating that SLy2 represents a newly identified host genetic factor that accounts for an
increased susceptibility to pneumococcal infections, when amplified in DS patients, the de-
velopment of novel therapeutic strategies might represent a promising approach to improve
their health status and thus, to prolong their general life span. Also other patients, who
suffer from reduced pneumococcal-specific immunity, like patients with selective polysac-
charide antibody deficiency, could benefit from therapies that aim to down-regulate SLy2. It
is important to notice that a global knock-out of SLy2 in mice did not affect the viability of
these animals, but rather improved their overall adaptive immunity, as reported recently [97].
Hence, with regard to unpredicted side-effects, the targeting strategy does not necessarily
have to be cell type-specific, which might facilitate the development of the latter.
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RNAi-based approaches - a future perspective
Down-regulation of mRNA and protein of specific targets can be easily achieved in cultured
cells by transient transfection of exogenous siRNA. In recent years, the suitability of this
mechanism for therapeutic uses was more and more investigated. However, the major chal-
lenge still represents the delivery of exogenous siRNA into the body. Problems which have
to be overcome are the efficient introduction into specific tissues and the circumvention of
immune reactions. Moreover, siRNA is a very unstable molecule, which is rapidly degraded
by serum nucleases. A quite promising approach to successfully deliver siRNA represents
the use of self-exosomes [83]. Exosomes are endogenous nanovesicles responsible for
cell-to-cell transports of mRNA and proteins, and thus, they are able to cross biological
barriers, such as cell membranes or the blood-brain-barrier. Due to their feature of be-
ing host-derived structures, immunogenicity following re-introduction is strongly reduced as
compared to chemically engineered transport vesicles. Interestingly, a recent study provided
evidence that the delivery of siRNA was achieved with the help of exosomes derived from
dendritic cells [5]. The authors demonstrated that siRNA was efficiently delivered into the
murine brain, where a knockdown of about 60 % at mRNA and protein levels was achieved
in neurons, microglia, and oligodendrocytes following intravenous injection of self-exosomes,
that had been packed with exogenous siRNA by electroporation. Moreover, another group
showed that exogenous siRNA was successfully delivered into human blood cells by using
plasma exosomes [96].
In conclusion, such therapeutic approaches could represent future strategies to efficiently
knock-down target genes in a tissue-specific manner, which might be of great value for the
therapy of genetic diseases. In due consideration of the multi-faceted phenotypes along with
trisomy 21, basic investigations on genotype-phenotype correlations might bring out poten-
tial target genes for these therapeutic strategies. Finally, the present work suggests SLy2 as
an interesting candidate to be investigated as a potential future therapeutic target to improve
the outcome of pneumococcal infections in immuno-compromised patients.
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